百年民族品牌拔頭籌 同仁堂醫養領航中醫發展

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 3月20日，"同仁堂"旗下核心醫療平臺--北京同仁堂醫養投資股份有限公司，（簡稱"同仁堂醫養"）正式啟動香港公開發售，邁出登陸香港聯交所主板的關鍵一步。作為同仁堂集團唯一戰略聚焦於中醫服務的核心板塊，同仁堂醫養的此番亮相，不僅是一家企業的資本化進程，更標志著中國最具代表性的百年中醫品牌，正式將標准化"中醫診療"推向國際資本市場。根據招股文件，同仁堂醫養（股份代號：02667.HK）此次全球發售108,153,500股H股，其中香港公開發售占10,815,500股（可予重新分配），國際發售占97,338,000股。每手500股，入場費約為4,191.85港元，發售價範圍定於每股7.30港元至8.30港元，以發售價中位數7.80港元計算，經扣除相關費用後，集資淨額預計約為7.71億港元。中金公司擔任其獨家保薦人及獨家整體協調人，設置綠鞋。航空港科技資本、Aurora SF兩大基石投資者已提前鎖定46%份額，彰顯對公司長期價值的信心。百年品牌鑄就競爭壁壘，分級網絡構建服務版圖在中國醫療健康行業的眾多參與者中，同仁堂醫養擁有一項難以複制的核心資產--357年同仁堂品牌背書。招股書顯示，同仁堂醫養定位於同仁堂集團旗下專注於中醫醫療服務的戰略子公司，聚焦中醫醫療服務核心賽道，構建"醫養結合、線上線下一體化"的特色服務體系，業務涵蓋中醫醫療服務、機構管理服務、健康產品銷售三大核心板塊，形成多層次、全周期的健康服務供給。品牌壁壘的量化體現尤為突出。數據顯示，公司推廣費用率僅為0.2%，遠低於行業平均水平。與行業平均銷售費用率約為12%-13%相比，同仁堂醫養低於其約60倍。這一數據意味著，當同業仍在大規模投入營銷獲客時，同仁堂醫養的患者已憑品牌認知主動就診--這是百年老字號鑄就的天然流量入口，也是競爭對手無法在短期內複制的結構性優勢。中醫分級網絡仍為行業先鋒。在業務布局方面，同仁堂醫養已建成分級中醫醫療服務網絡，擁有12家自有線下醫療機構以及1 家互聯網醫院，同時向12 家公立線下醫療機構提供管理服務，覆蓋北京、浙江、上海、山西、貴州、遼寧、陝西等核心區域，形成"連鎖醫院-基層醫療機構-互聯網醫院"的三級架構，實現了全國服務網絡的高效協同。其中，連鎖醫院承擔疑難重症的多學科診療職能，基層醫療機構（門診部、診所、社區醫院）負責常見病、慢病管理和日常健康維護，互聯網醫院則打破時空限制，將服務半徑延伸至全國。三級架構分層協同、高效配置醫療資源，為後續全國化擴張奠定了可複制的基礎模型。品牌及網絡效能持續高速釋放。數據顯示，2024年其網絡內總就診人次達297.7萬，2022年至2024年的複合年增長率高達51.9%。會員數量從43.6萬人增至76.7萬人，客戶黏性與複購率穩步提升。旗下醫療機構實現醫保定點全覆蓋，患者就醫便利性與支付可及性得到有力保障。多輪驅動式外延擴張，整合賦能標准化連鎖本次 IPO 核心看點，在於同仁堂醫養以"戰略性並購、輕資產新建及管理服務輸出"三種方式實現規模與質量雙躍升。公司立足百年品牌勢能，采取"網絡整合+標杆管理+全國複制"的擴張路徑，精准卡位區域優質中醫機構，快速補齊網絡、專科、客流與供應鏈全鏈路。2022年公司完成對浙江三溪堂保健院、三溪堂國藥館的控股收購，一舉拿下浙江區域安宮牛黃丸系列獨家經銷權，打通醫療服務與健康產品協同變現通道；2024年相繼收購上海承志堂等醫療機構控股權，強勢切入長三角核心市場，實現京滬浙多點聯動。衡量一家連鎖醫療企業並購戰略成敗的關鍵，不在於"買了多少"，而在於"整合得多好"。同仁堂醫養依托采購協同平臺、雲HIS與BIS數字化系統，對收購機構實施醫療質量、運營效率、成本管控一體化管理，推動被投機構快速融入同仁堂體系、釋放盈利潛力。與此同時，公司的管理服務毛利率超70%，與高毛利健康產品、穩定醫療服務業務形成互補，構建韌性極強的盈利結構。同仁堂醫養並非傳統的重資產醫院集團，而是走出一條"輕資產管理式"醫療集團路徑，為未來規模化擴張提供了更具彈性的增長空間。基本面穩定有韌性，行業打開增長空間財務表現也印證同仁堂醫養的發展模式。2022-2024年，公司營收從9.11億元增至11.75億元，收入CAGR達13.6%，毛利潤CAGR更高達24.8%；2024年淨利潤4620萬元、經調整淨利潤6173萬元，同比增長29.0%，呈現"增收更增利"的高質量增長特征。期間費用率從2022年的17.1%下降至2025年前三季度的13.6%，下降3.5個百分點，標准化運營和數智化轉型的效率紅利持續釋放。經營性現金流轉化率達87.2%，賬面現金2.25億元，利息覆蓋充裕，財務安全邊際充足。企業正在從"規模擴張期"平穩過渡至"利潤釋放期"--這正是連鎖醫療企業盈利質量躍升的關鍵階段。從行業趨勢來看，中醫醫療服務正處於政策驅動與需求擴容的雙重紅利期。據弗若斯特沙利文數據，中國中醫醫療服務市場規模預計2029年將達1.62萬億元，2024年至2029年CAGR為9.9%。在人口老齡化持續深化和"全民養生"消費趨勢下，中醫醫養賽道的確定性增長邏輯清晰。此外，在中醫藥振興政策與人口老齡化需求雙重驅動下，中醫醫療服務行業進入整合提速期。同仁堂醫養憑借品牌壁壘、並購整合能力、標准化複制體系三大核心優勢，在行業集中度提升過程中占據主動。本次IPO募集資金將重點投向醫療網絡擴張、服務能力升級等。同仁堂醫養以資本為翼，以醫養為本，將百年民族品牌底蘊轉化為現代醫療服務競爭力。此次港股上市，不僅打開全國化擴張空間，更為投資者分享中醫醫養黃金賽道紅利，領航中醫藥醫療服務行業高質量發展新征程。轉載自中國證券報 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-24

TINGYI (CAYMAN ISLANDS) HOLDING CORP. Business Momentum Sustained in 2025, United for a New Journey, with GPM Rising to 34.8%, Profit Attributable to Shareholders Up 20.5% YoY

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - On March 23, 2026, Tingyi (Cayman Islands) Holding Corp. (0322.HK, the “Company”, together with its subsidiaries, the “Group”) is pleased to announce its 2025 annual results. In 2025, amid drastic changes in consumer behaviours and a complex market environment, the Group remained firmly committed to the consumer-centric approach, advanced the high-quality development in a coordinated manner, promoted product innovation and upgrades to precisely meet the demands of diverse scenario-based needs, while accelerating the expansion into high-growth channels. It comprehensively improved overall operational efficiency and drove steady growth of all key financial indicators. For the twelve months ended on December 31, the Group’s revenue decreased by 2.0% year-on-year to RMB 79.068 billion. Among which, the revenue from the Instant Noodles Business was RMB28.421 billion, while the revenue from the Beverages Business was RMB50.123 billion. The gross profit margin grew 1.7 percentage points to 34.8% year-on-year, EBITDA increased by 10.2% year-on-year to RMB 10.607 billion. The profit attributable to shareholders of the Company increased significantly by 20.5% year-on-year to RMB4.501 billion. The directors recommended the payment of a final dividend and a special final dividend of RMB39.92 cents and RMB39.92 cents per ordinary share respectively. Dividend payout ratio for the year remained at 100%.Financial Summary For the twelve months ended 31 December RMB’00020252024ChangeRevenue79,068,02280,650,914↓ 2.0%Gross margin34.8%33.1%↑ 1.7ppt.Gross profit of the Group27,531,70426,695,643↑ 3.1%EBITDA10,606,5229,627,802↑ 10.2%Profit for the period5,175,8524,322,135↑ 19.8%Profit attributable to owners of the Company4,500,6983,734,429↑ 20.5%Earnings per share (RMB cents)   Basic79.8666.28↑ 13.58 centsDiluted79.8466.28↑ 13.56 centsAs at 31 December 2025, cash at bank and on hand (including long-term time deposits) was RMB19,486.056 million, representing an increase of RMB3,483.388 million when compared to 31 December 2024. Gearing ratio was -29.8%.In 2025, China's economy demonstrated resilience with a 5% year-on-year GDP growth. However, the food and beverage market entered into the stage of stock competition and demand upgrading for functional and emotional values. Brand, quality, and flavors remained key drivers of purchasing decisions. Additionally, emerging formats such as instant retail, snack discount stores, and membership stores had brought about drastic changes in channels and consumer behaviors. Against the backdrop of intensifying market competition and evolving consumption patterns, a company's core competitiveness increasingly lies in building a strong moat for their core brands. Those that continuously drive product innovation and channel optimization around consumer needs will be more agile in capturing market opportunities, strengthening consumer trust, and ultimately achieving high-quality and sustainable long-term development.In 2025, the gross profit of the Instant Noodles business improved steadily. The Group’s revenue from the Instant Noodles Business was RMB28.421 billion, which grew slightly year-on-year, accounting for 35.9% of the Group’s total revenue. During the year, due to favorable raw material prices and selling prices, the gross profit margin of instant noodles expanded by 1.1 percentage points year-on-year to 29.7%, and the profit attributable to shareholders of the Company for the year of 2025 in the Instant Noodles Business increased significantly by 10.1% year-on-year to RMB 2.252 billion, driven by the year-on-year increase in gross profit margin. During the year, in the face of intensifying industry competition, the Instant Noodles Business steadily advanced its core strategy of “consolidating blockbuster products, seizing the popular flavors track, and cultivating innovative products.” By continuously improving the product portfolio and forging deep collaborations with popular IPs, it effectively amplified brand presence and steadily optimized gross margin structure. On the product front, the business relied on deep cultivation of core blockbuster products and iterative flavor upgrades, while closely aligning with evolving consumer trends to precisely target the health-focused and premium market segments, tapping into new growth opportunities. On the marketing front, it leveraged mainstream social platforms such as Bilibili and Xiaohongshu to conduct omnichannel communication, combined with cross-industry collaborations with well-known IPs to reinforce the brand perception of high-end and convenient consumption. As a result, brand influence and market recognition improved significantly. Meanwhile, guided by aerospace-grade quality standards, the business promoted the full application of aerospace patented temperature control technology in the production line, fully demonstrating the brand’s differentiated advantages in product quality and technological innovation.The Beverages Business firmly executed the strategy of “consolidating core products and developing innovative products”, the revenue from the Beverages Business was RMB50.123 billion, accounting for 63.4% of the Group’s total revenue. During the year, due to favorable raw material prices and optimized product mix, the gross profit margin of Beverages expanded by 2.2 percentage points year on-year to 37.5%. Driven by a year-on-year expansion of gross profit margin, the profit attributable to shareholders of the Company in the Beverages Business for the year of 2025 increased significantly by 18.5% year-on-year to RMB 2.274 billion. During the year, the Beverages Business strengthened its core category advantages and proactively positioned itself in emerging tracks, establishing a collaborative growth model across the full product portfolio. On the product front, while consolidating core products, it continuously expanded into incremental growth segments by launching high-quality sugar-free offerings and aligning with the wellness consumption trend to create herbal wellness scenarios, successfully opening up new growth spaces such as products made from homologous medicinal and food materials. On the marketing front, the Company deepened IP collaborations to broaden audience reach, enhanced its presence in cultural tourism channels and high-end hotel partnerships, and targeted premium consumption scenarios. These efforts consistently elevated brand value, providing strong support for the business to achieve steady operations and sustainable growth.Mr. Wei Hong-Chen, Chief Executive Officer, commented, “As the first year of the 15th Five-Year Plan period, 2026 is expected to see expanding domestic demand become a key driver of economic growth under a more proactive and effective macroeconomic policy, while the consumer market will also usher in a critical window of profound transformation. The food and beverage industry will closely follow the theme of high-quality development, and consumption stratification will become more refined. Functional attributes, emotional resonance, and green concepts are shifting from trends to mainstream factors, becoming core elements driving brand growth. In the face of opportunities and challenges in the new cycle, the Group will be guided by the spirit of “Back to Day 1” as its strategic direction, embracing the efficiency, agility and entrepreneurial drive of our founding days, and building a platform that encourages honesty, bold experimentation and mutual growth, thus fully unleashing the vitality of all employees. While unleashing organizational vitality, we will continue to strengthen our foundational R&D capabilities and digital operation systems. Rooted in the health needs of the nation, we will drive product iteration and upgrades through technological innovation, continuously elevate product value, and align high-quality supply with the evolving consumption landscape. Adhering to the “economic-ESG” sustainable development philosophy, we will internalize social responsibility as the foundation of our development, solidify user trust through quality products, build a brand moat with long-term value, and create a sustainable and stable return system for shareholders, propelling the Group toward steady and sustained progress in the new stage of high-quality development.”About Tingyi (Cayman Islands) Holding Corp. (0322.HK)Tingyi (Cayman Islands) Holding Corp. (the “Company”), and its subsidiaries (the “Group”) specialise in the production and distribution of instant noodles and beverages in the People’s Republic of China (the “PRC”). The Group started its instant noodle business in 1992, and expanded into instant food business and beverage business in 1996. In March 2012, the Group further expanded its beverage business by forming a strategic alliance with PepsiCo for the beverage business in the PRC. The Company exclusively manufactures, bottles, packages, distributes and sells PepsiCo soft drinks in the PRC. After years of hard work and accumulation, “Master Kong” has become one of the best-known brands among consumers in the PRC.For enquiries, please contact:Investor EnquiriesInvestor Relations Team, Tingyi (Cayman Islands) Holding Corp.E-mail: ir@tingyi.comChristensen China LimitedStephanie ChenE-mail: stephanie.chen@christensencomms.comTel: +852 2117 0861 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-24

康師傅控股有限公司2025年業務持續向好 凝心聚力再啟新程

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 2026年3月23日，康師傅控股有限公司（0322.HK，以下簡稱「公司」，連同其附屬公司「集團」）發佈2025年年度業績公告。2025年，在消費行為劇烈變革與市場環境複雜多變的背景下，本集團始終堅持以消費者為中心，統籌推進高質量發展，推動產品創新升級，精准滿足多元場景需求，同時加速開拓高增長渠道，全面提升整體運營效能，推動各項財務指標穩健發展。截至2025年12月31日止十二個月，集團收益同比衰退2.0%至790.68億人民幣。其中，方便面事業收益284.21億人民幣，飲品事業收益為501.23億人民幣。毛利率同比提高1.7個百分點至34.8%，EBITDA同比增長10.2%至106.07億人民幣，本公司股東應佔溢利同比成長20.5%至45.01億人民幣。董事會建議派發末期股息每股普通股人民幣39.92分及特別末期股息每股普通股人民幣39.92分，全年派息率達100%。財務摘要 截至12月31日止12個月 人民幣千元2025年2024年變動收益79,068,02280,650,914↓ 2.0%毛利率（%）34.8%33.1%↑ 1.7個百分點集團毛利27,531,70426,695,643↑ 3.1%扣除利息、稅項、折舊及攤銷前盈利（EBITDA）10,606,5229,627,802↑ 10.2%本期溢利5,175,8524,322,135↑ 19.8%本公司股東應占溢利4,500,6983,734,429↑ 20.5%每股溢利（人民幣分）   基本79.8666.28↑ 13.58分攤薄79.8466.28↑ 13.56分於2025年12月31日之銀行存款及現金（含長期定期存款）為人民幣19,486,056千元，相較2024年12月31日增加人民幣3,483,388千元，淨負債與資本比率為-29.8%。2025年，中國經濟在GDP同比5%的增長中展現韌性。但食品飲料市場進入存量博弈，以及對功能價值與情緒價值需求升級階段。品牌、品質與風味仍是購買決策的重要驅動因素。此外，即時零售、零食折扣店、會員店等新興業態帶來渠道與消費行為劇烈變革。在市場競爭日趨激烈、消費行為持續演變的背景下，企業的核心競爭力愈發體現在核心品牌的護城河建設。能夠圍繞消費者需求，持續推動產品創新與渠道優化的企業，將更敏捷地捕捉市場機遇，鞏固消費者信任，進而實現高質量、可持續的長遠發展。2025年，方便面事業的毛利結構持續改善。方便面事業收益為284.21億人民幣，同比微幅增長，占集團總收益35.9%。年內，因原材料價格及售價有利，使方便面毛利率同比提高1.1個百分點至29.7%，由於毛利率同比提高帶動，令方便面事業2025年全年的本公司股東應占溢利同比大幅增長10.1%至22.52億人民幣。年內，面對日趨激烈的行業競爭，方便面業務扎實推進「鞏固大單品、佔領大口味賽道、培育創新產品」的核心戰略，通過持續完善產品矩陣，與熱門IP深度聯動，有效放大品牌聲量，穩步優化毛利結構。產品端，依託核心大單品深耕與口味迭代升級，同時緊密貼合消費趨勢變化，精准佈局健康化、高端化賽道，精准切入新增量市場。營銷端，依託B站、小紅書等主流社交平台開展全域傳播，疊加知名IP跨界合作，深化高端便捷的品牌認知，品牌影響力與市場認知度顯著提升。同時，以航天品質為引領，推動航天專利溫控技術在生產線全面落地應用，充分彰顯品牌在產品品質與科技含量的差異化優勢。飲品事業堅定實施「鞏固核心單品、發展創新產品」戰略。飲品事業整體收益為501.23億人民幣，占集團總收益63.4%。年內，因原材料價格有利及產品組合優化，使飲品毛利率同比提高2.2個百分點至37.5%。由於毛利率同比提高帶動，令飲品事業2025年全年本公司股東應占溢利同比大幅提高18.5%至22.74億人民幣。年內，飲品事業通過深化核心品類優勢與前瞻性佈局新興賽道，構建全品類協同增長格局。產品端，在穩固核心單品的基礎上，持續拓展增量賽道，推出高品質無糖產品，並緊扣養生消費趨勢，打造草本養生場景，成功開闢藥食同源等新增量空間。營銷端則持續強化IP深度合作拓寬受眾圈層，同時強化文旅渠道佈局及高端酒店合作，錨定高端消費場景，持續提升品牌價值，為業務實現穩健經營與可持續增長提供有力支撐。康師傅首席執行官魏宏丞先生表示：「2026年作為「十五五」開局之年，預計在更加積極有為的宏觀政策下，擴大內需將成為經濟增長的關鍵著力點，消費市場也將隨之迎來深度變革的關鍵窗口。食品飲料行業圍繞高質量發展主線持續演進，消費分層愈加精細，功能價值、情緒共鳴與綠色理念正從趨勢走向主流，成為驅動品牌增長的核心要素。面對新週期中的機遇與挑戰，集團將以「Back to Day 1」的精神為戰略引領，回歸創業初期的高效敏捷與狼性拼搏文化，打造敢講真話、勇於嘗試、共同成長的平台，充分激發全員活力。在釋放組織活力的同時，我們將持續夯實基礎研發能力與數字化運營體系，立足國民健康訴求，以科技創新驅動產品迭代升級，推動產品價值不斷躍遷，以高品質供給適配新消費結構。秉持「economic-ESG」可持續發展理念，我們將社會責任內化為發展底色，通過優質產品夯實用戶信賴，以長期價值構建品牌護城河，為股東打造可持續的穩健回報體系，推動集團在高質量發展新階段行穩致遠。」關於康師傅控股有限公司(0322.HK)康師傅控股有限公司（「本公司」）及其附屬公司（「本集團」）主要在中國從事生產和銷售方便面及飲品。本集團於1992年開始生產方便面，並自1996年起擴大事業至方便食品及飲品；2012年3月，本集團進一步拓展飲料事業範圍，完成與PepsiCo中國飲料事業之戰略聯盟，開始獨家負責制造、灌裝、包裝、銷售及分銷PepsiCo於中國的非酒精飲料。「康師傅」作為中國家喻戶曉的品牌，經過多年的耕耘與積累，深受中國消費者喜愛和支持。如有垂詢，請聯絡：投資者查詢康師傅控股有限公司投資者關係團隊電郵：ir@tingyi.com匯思訊中國有限公司陳敏芝電郵：stephanie.chen@christensencomms.com電話：+852 2117 0861 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-24

全景業務佈局+AI雙輪驅動 麥迪衛康業績扭虧為盈打開廣闊成長空間

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 3月23日，麥迪衛康正式發佈2025年度業績公告。數據顯示，公司年內溢利約人民幣698萬元，盈利能力顯著修復，全年扭虧為盈，經營性現金流狀況持續好轉。業績改善主要得益于“AI+數字化”帶動核心主營業務持續穩健增長，疊加公司聚焦高毛利優質項目，有效帶動整體毛利水平顯著提升。此次公司財務表現展現出強勁的修復彈性，是公司發展歷程中的重要里程碑。一方面，標誌著公司聚焦主業、優化業務結構的戰略取得實質性成效，經營質量與盈利能力邁入全新階段，為後續穩健發展築牢財務根基；另一方面，充分印證公司核心業務具備強勁增長韌性與市場競爭力，高毛利項目佈局持續釋放效益，也為公司深化醫療健康服務佈局、拓展優質業務版圖注入更強信心，進一步鞏固行業競爭力與可持續發展能力。3C服務體系覆蓋全產業鏈 技術創新構築核心競爭力經營效率的跨越式進步，離不開公司清晰的業務佈局與精准的戰略定位。在業務佈局方面，麥迪衛康以創新數字醫療服務提供商為定位，打造獨具競爭力的「3C服務體系」，涵蓋專業醫學內容服務（Content）、高端學術會議服務（Conference）、企業市場推廣服務（Corporation）三大核心領域，形成了覆蓋醫療全產業鏈的服務閉環，為業務高質量發展筑牢根基。2025年，公司數字化醫學平台的運營步入高質量發展的新階段。該平台不僅實現了專業醫療群體的高密度覆蓋，更在海量的學術交流與衛教傳播中，構築起一套精準、專業且具備高度粘性的知識服務體系。這種深度的數字化轉型，不僅顯著提升了醫學內容的傳播效能與學術影響力，更在賦能醫生臨床決策、助力健康知識普及方面發揮了關鍵作用，轉化為推動行業進步的實質性力量，進一步鞏固了公司在數字醫療生態中的引領地位。持續的技術創新，是驅動麥迪衛康高質量增長的核心引擎。在技術研發領域，公司擁有多項軟件著作權與發明專利，自主研發的「長頸鹿」系列數智平台已吸引數十萬名醫生入駐，顯著提升醫療服務與運營管理效率。2024年，公司持續深化AIGC場景落地，創新推出「AI智能體+醫生眾創」模式，助力醫生回歸高價值診療與科研工作；同時依託區塊鏈技術成功獲得數據服務商資質，實現醫學內容確權與授權運營，為醫療數字化生態建設樹立行業標杆。2025年，公司深入推進AI智能體的研發與場景應用探索，致力於與醫療專業人士協同，打造「AI+人工」深度融合的醫學內容數據標註及版權內容生產體系，並與數字資產交易平台業務形成有機銜接。此外，依托专病管理AI智能体所取得的阶段性突破，公司正进一步将数智化能力向产业上下游延伸，前瞻性地探索智能专病机器人赛道；同时，通过对柏慧康生物的战略投资，公司正积极探索在多组学创新检测领域的落地应用并已取得阶段性进展，借此构建起立体化的医疗创新服务网络。全國服務網絡縱深覆蓋 打開長期價值成長空間依託成熟的業務體系與核心技術支撐，麥迪衛康已搭建起覆蓋全國的專業服務網絡。目前，公司在全國設立近10家經營機構，重點佈局北京、上海、南京等核心醫療樞紐城市，服務合作三級醫療機構超3000家，其中包括北京天壇醫院、阜外醫院等國內頂尖三甲醫院。同時，公司深度參與卒中中心、胸痛中心等重點專科建設，構建起縱向貫通、橫向協同的全域專科醫療服務體系，為業務高效落地與市場持續拓展提供了堅實保障。廣泛覆蓋的服務網絡與專業高效的服務能力，讓麥迪衛康積累起優質且多元的客戶群體，行業龍頭地位持續鞏固。在數字醫療領域，公司自有互聯網醫療平台已匯聚註冊醫生超5萬名、註冊患者近36萬人次，2025年線上諮詢量突破50萬次，同比增長超19%，實現優質醫療資源高效觸達，有效緩解醫療資源分配不均難題。從行業發展趨勢來看，在人口老齡化加劇、慢性病管理需求攀升、政策持續賦能及AI數字技術深度滲透等多重驅動下，中國數字醫療產業正迎來黃金髮展期，據中商產業研究院數據預測，2025年中國數字醫療市場規模預計達5800億元，2031年突破1.2萬億元，廣闊的市場增量為麥迪衛康這類具備核心技術壁壘與全鏈條佈局的領軍企業，提供了持續成長與價值釋放空間。麥迪衛康以「3C服務體系」為基座，以技術創新與服務升級為引擎，憑藉覆蓋全國的服務網絡、廣泛優質的客戶資源以及前瞻性的戰略佈局，在行業內構建了獨特的競爭優勢與地位。未來，隨著數字醫療產業的持續升溫與公司業務的不斷深化，公司將緊抓醫療智能化轉型的時代機遇，聚焦AI小模型賦能，全面拓展業務版圖，夯實「AI+區塊鏈」技術底座，探索搭建全流程智能閉環體系。同時以「醫學專業服務+數字化技術」雙輪驅動，持續拓寬業務邊界、優化內部運營效能，在數字醫療賽道上實現更高質量的發展，打開廣闊成長空間。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-24

International Career Institute Marks 20 Years with 100 Scholarships to Support Flexible Online Study

Sydney, Australia--(ACN Newswire via SeaPRwire.com - March 23, 2026) - The International Career Institute (ICI) is marking its 20th anniversary with the launch of 100 scholarships, in a milestone initiative designed to widen access to flexible, career-focused online study. The scholarship announcement comes as more students look for practical ways to upskill, change careers or strengthen their professional credentials without putting work or family life on hold.New scholarships launched as International Career Institute celebrates two decades of career-focused educationTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10373/288837_60f2135b4402f876_001full.jpgOver the past two decades, the International Career Institute has built its reputation as an independent private provider of online education focused on practical, job-relevant learning. ICI offers 57 courses, has supported 58,453 students, and has learners in 191 countries, reflecting a substantial international footprint.The anniversary scholarship campaign is intended to do more than mark a birthday. It reflects a wider shift in the education market, where students are increasingly prioritising flexibility, affordability and direct career outcomes. ICI positions itself around exactly those needs: online delivery, self-paced study, personal tutor support, included course materials, flexible payment plans and career services aimed at helping graduates move into employment or advance in their chosen field.Applicants for the Leadership Scholarships are asked to demonstrate leadership potential or current leadership responsibilities and to complete an application process that outlines their background and motivation for study. Applicants facing financial disadvantage will be given priority. The scholarship forms part of a broader ICI scholarship offering and positions the initiative as a way to recognise leadership and help recipients take the next step in their development.For many adult learners, flexibility is not simply an added benefit; it is the condition that makes study possible. At the International Career Institute, students can study at their own pace, with no classes to attend and no additional textbooks or materials to purchase. Its online study model is structured around module-based written assessments rather than traditional exams, while students receive guidance and feedback from personal tutors throughout the course.Dr Michael Machica, Director of the International Career Institute, said the anniversary was both a celebration of the institution's history and a statement of intent for its future."Reaching 20 years is a proud milestone for the International Career Institute and a moment to reflect on how education has changed. From the beginning, our goal has been to make career-focused learning more flexible, more practical and more accessible for people whose lives do not fit the traditional study model. Over the next 20 years, we see ICI continuing to expand its reach, strengthen its industry relevance and help even more learners build meaningful careers through online education that works in the real world."That long-term focus on accessibility and employability remains central to the International Career Institute brand. Central to ICI's offering is tutor support, affordable pricing, interest-free payment plans, included materials and graduate career services. Those services include assistance with resumes, job searches, cover letters and interview preparation - features that help distinguish ICI in a competitive online learning market where students are increasingly outcome-focused.ICI's programmes are developed in consultation with industry experts and aligned with real-world job opportunities. That proposition - flexible study paired with career relevance - has become increasingly important as more learners seek education that fits around existing work, business, or family commitments while still contributing to employability and advancement.The release of 100 scholarships also gives the anniversary a broader public-interest dimension. In a cost-conscious environment, even motivated learners can hesitate when considering professional study. By offering scholarships focused on leadership and development, ICI is positioning its 20th anniversary not simply as a milestone but as an opportunity to invest in the next generation of professionals and career changers.Prospective students can explore scholarship eligibility, course options and the International Career Institute online study model through the institute's website, where they can also view course pages, student reviews and information about graduate support. For those considering a career change, promotion pathway or a more flexible way to formalise their skills, the anniversary scholarships create a timely reason to act.About International Career InstituteICI is an independent private provider of online education and training established in 2006. It offers career- and lifestyle-focused courses through a fully online, self-paced study model supported by personal tutors and graduate career services.Media ContactFor media enquiries, please contact:Email: info@ici.net.au Website: www.ici.net.auInternational Career InstituteTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10373/288837_60f2135b4402f876_002full.jpgTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/288837 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-23

Doubleview Gold Clarifies Preliminary Economic Assessment Results for the Hat Project; Updated Scenario B NPV Increased to C$7.27 Billion

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - March 23, 2026) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) ("Doubleview" or the "Company") provides clarification to its news release dated March 2, 2026, announcing the Preliminary Economic Assessment ("PEA") for the Company's 100% owned Hat Project in northwestern British Columbia.Following publication of the March 2, 2026 news release, Mineit Consulting Inc., the independent engineering firm responsible for the PEA, completed a further review of the application of certain processing cost assumptions relating to the scandium recovery circuit in Scenario B. As a result of this review, the after-tax NPV(5%) for Scenario B at consensus metal prices has been updated to C$7.27 billion from C$6.94 billion and IRR of 19%. The update also results in an increase in Scenario B after-tax NPV(5%) at spot metal prices to C$14.85 billion from C$14.52 billion and IRR of 32%.The updated Scenario B results further demonstrate the economic contribution of the scandium recovery circuit and increase the difference in after-tax NPV between the base case (Scenario A2) and Scenario B to C$547 million.The cobalt grade reported in Table 1 of the Company's March 2, 2026 news release was inadvertently shown as 0.78 g/t Co. The correct value is 78 g/t Co, consistent with Table 5 of the release. This discrepancy was limited to the summary table presentation and does not affect the PEA results or conclusions.These clarifications do not change the overall conclusions of the PEA and further highlight the strong economics of the Hat Project, including the potential value contribution from scandium recovery.Corrected highlights of the PEA reflecting the updated Scenario B economics are presented below.NPV:After-tax NPV(5%) of C$6.73 billion and IRR of 23% at Consensus Metal Prices After-tax NPV(5%) of C$13.53 billion and IRR of 39% at Spot Metal PricesNPV Including scandium and the associated processing circuit: After-tax NPV(5%) of C$7.27 billion and IRR of 19% at Consensus Metal PricesAfter-tax NPV(5%) of C$14.85 billion and IRR of 32% at Spot Metal PricesThree processing scenarios were evaluated-Scenario A1 (A1) a Cu-Au-Ag-Co flotation base case using current testwork recoveries1, Scenario A2 (A2), the same base case using expected recoveries1, and Scenario B (B), a Cu-Au-Ag-Co flowsheet with an added hydrometallurgical circuit and scandium recovery circuit, with results indicating the Project is financially attractive even without the scandium component.Highlights:Robust Project Economics: The PEA demonstrates a high-margin operation with an After-Tax NPV(5%) of C$4.96 billion (A1), C$6.73 billion (A2), or C$7.27 billion (B), and an IRR of 19% (A1), 23% (A2), or 19% (B) at analyst consensus metal prices2. Using a spot-price scenario3, the Project delivers a compelling after-tax NPV(5%) of C$11.05 billion (A1), 13.53 billion (A2), or C$14.85 billion (B) and an IRR of 34% (A1), 39% (A2), or 32% (B).Sensitivity Highlight: Project economics show the greatest leverage to overall metal prices, with NPV (5%) ranging from C$3.2 billion to C$10.2 billion (IRR: 14%-32%) at ±20% on all metals; even under additional +20% CAPEX and +20% OPEX sensitivities, applied on top of a 25% contingency already embedded in the base case, all scenarios deliver IRRs of 16% or better, and Scenario B provides additional scandium oxide upside with NPV(5%) of C$6.5 billion-C$8.1 billion (IRR: 18%-20%) at ±40% metal price.Scale and Longevity: The mine plan supports a multi-decade life of 25 years at a 120,000 tonnes-per-day processing rate, underpinned by a resource base of 609 Mt at 0.43% CuEq4 in the Measured and Indicated categories and 503 Mt at 0.41% CuEq4 in the Inferred category.High-Output Production Profile B: Envisioned as a conventional large-scale open-pit operation, the Project is expected to produce an average of over 74 kt of copper, 254 koz of gold, 376 koz of silver and 2.7 kt of cobalt annually during the first 10 years, with life-of-mine (LOM) average production of 67.6 kt Cu, 217 koz Au, 348 koz Ag, 2.5 kt Co, and 128 tonnes of scandium oxide per year. (NOTE: based on publicly reported 2024 North American cobalt mine production of approximately 3,800-4,000 tonnes (Natural Resources Canada; U.S. Geological Survey), the projected cobalt output is estimated to represent approximately 69% of current regional mined supply).Strategic Importance for Critical Minerals: The Project is positioned as a primary North American source of copper, scandium, and cobalt. With approximately 2.42 billion pounds of copper, 80 million pounds of cobalt and 2,415 tonnes of scandium oxide contained5 in the Measured and Indicated categories, the Project represents an important discovery of critical minerals.Stable, Supportive Jurisdiction: Located in a premier mining district in British Columbia, the Project benefits from a stable regulatory environment. The Company is committed to engaging with local First Nations in a respectful manner and to working toward positive and constructive relationships as the Project advances.Catalyst for Development: The PEA serves as the technical foundation for an immediate transition into a Pre-Feasibility Study (PFS), providing a clear roadmap for early works and permitting activities in 2026 and 2027.Farshad Shirvani, President and CEO of Doubleview Gold Corp., commented, "The results of this PEA confirm the scale, strength and long-term potential of the Hat Project. Delivering a post-tax NPV(5%) of up to C$6.73 billion and IRR of up to 23% at consensus prices, and even stronger metrics at spot prices, validates years of disciplined exploration and technical work by our team. Hat is demonstrating Tier 1 characteristics with a 25-year mine life, strong annual production profile and meaningful free cash flow generation. Importantly, the Project stands on its own without reliance on scandium, while still preserving significant upside from critical minerals as markets mature. We are excited to advance Hat to Pre-Feasibility and continue building a major Canadian critical metals project."Doubleview acknowledges that the Project is located on the traditional territories of the Tahltan Nation and the Taku River Tlingit First Nation, and recognizes their enduring relationship to and stewardship of the land and waters. Doubleview is committed to respectful, transparent, and ongoing engagement with First Nations and local communities whose territories overlap the Project area and access routes, with a focus on protecting water and the environment and advancing responsible development.PEA OVERVIEWThe PEA contemplates a conventional open-pit mine and processing operation with a 25-year mine life at a 120,000 t/d (42 Mt/a) plant throughput. Two processing pathways were evaluated, A1 and its alternative, A2, and B: the first alternative, A, is a Cu-Au-Ag-Co flotation concentrator with two recovery cases based on current metallurgical testwork, and A2, reflecting expected performance (Figure 1); and B, a full circuit that retains the base flowsheet and adds a downstream hydrometallurgical scandium recovery circuit (Figure 2).The tailings storage facility is a centreline-raised facility built with compacted cycloned sand from tailings underflow, and engineered drainage for stability, with site-contact waters (including seepage and pit dewatering) recycled to the process plant and final closure involving pond drainage and reclamation. The Project is expected to rely on grid power via an extended transmission line.Tables 1 to 3 summarize the key results of the PEA, including production, operating costs, capital expenditures, and the principal financial metrics; the sections that follow provide additional detail on the underlying assumptions, project design, and study outcomes.Table 1: PEA Study Summary-ProductionMetric UnitScenario A1Scenario A2Scenario BMining SummaryStrip ratiot:t1.60Production Summary LOMAverage Annual ThroughputMt42CuEq Head Grade6, 7%0.42Cu Head Grade%0.19Au Head Gradeg/t0.19Ag Head Gradeg/t0.51Co Head Gradeg/t77.73Sc Head Grade6g/t28.35Cu Recovery%8089858Au Recovery%6675898Ag Recovery%5353688Co Recovery%3030788Sc Recovery%N/A728Overall Mass of Tailings to Process9%N/A12.5Year of Production Start of Sc2O38yearN/A4Average Annual Cu Productionkt63.670.867.6Total Cu Productionkt1,590.51,769.41,689.9Average Annual Payable Cukt61.768.765.7Total Payable Cukt1,542.81,716.31,642.2Average Annual Au Productionkoz161.1183.1217.3Total Au Productionkoz4,028.24,577.55,432.0Average Annual Payable Aukoz153.1173.9207.5Total Payable Aukoz3,826.84,348.75,188.6Average Annual Ag Productionkoz271.3271.3348.0Total Ag Productionkoz6781.66,781.68,700.9Average Annual Payable Agkoz244.1244.1318.6Total Payable Agkoz6,103.46,103.47,965.3Average Annual Co Productionkt1.01.02.5Total Co Productionkt23.923.962.2Average Annual Payable Cokt0.80.82.3Total Payable Cokt19.119.156.3Average Annual Sc2O3 ProductiontN/A128.4Total Sc2O3 ProductiontN/A3,209.5Total Sc2O3 PayabletN/A3,049.0 Table 2: PEA Study Summary-Operating CostMetricUnitScenario A1Scenario A2Scenario BOperating Cost Average Mine Operating CostsC$/t-moved2.32Average Mine Operating CostsC$/t-milled6.03Processing Operating Cost10C$/t-milled7.937.9310.84Sc2O3 Processing Cost11C$/kg Sc2O3N/A939.55General & AdministrativeC$/t-milled2.562.562.56Total Operating CostsC$/t-milled16.2216.2221.92 Table 3: PEA Study Summary-Capital Expenditure and Financial MetricsMetricUnitScenario A1Scenario A2Scenario BCapital Expenditure Initial Capital CostsC$M3,5523,6013,828Sustaining Capital CostsC$M2,7552,7554,006Closure and Reclamation CostC$M503Financial Metrics Exchange RateCAD/USD1.37Long Term Copper PriceUS$/lb4.88Long Term Gold PriceUS$/oz3,272.60Long Term Silver PriceUS$/oz50.22Long Term Cobalt PriceUS$/lb19.57Long Term Scandium Oxide PriceUS$/kgN/A1,500Average Annual EBITDAC$M8861,0711,284Total EBITDAC$M22,16226,77032,101Average Annual Free Cash Flow (Pre-tax)C$M7569401,104Free Cash Flow (Pre-tax)12C$M18,90423,51127,592Total Provincial Tax (inc. BC Mineral Tax)C$M(4,029)(5,090)(6,019)Total Federal TaxC$M(1,274)(1,859)(2,308)Total TaxesC$M(5,303)(6,949)(8,327)Average Annual Free Cash Flow (Post-tax)C$M544662771Free Cash Flow (Post-tax)12C$M13,60116,56219,265Total Free Cash Flow (Pre-tax)13C$M15,35219,91023,764Total Free Cash Flow (Post-tax)12C$M10,05012,96115,437NPV 5% (Pre-tax)C$M7,88310,57611,567NPV 5% (Pre-tax)US$M5,7547,7208,443IRR (Pre-tax)%242923Payback (Pre-tax)yearsYear 5Year 4Year 6NPV 5% (Post-tax)C$M4,9636,7277,274NPV 5% (Post-tax)US$M3,6234,9115,309IRR (Post-tax)%192319Payback (Post-tax)YearsYear 6Year 5Year 7 Table 4 shows the Sensitivity analysis using after-tax NPV(5%) and after-tax IRR.Table 4: Sensitivity AnalysisVariableCase(%)Metal PriceScenario A1Scenario A2Scenario BNPV (5%) C$MIRR(%)NPV (5%)C$MIRR(%)NPV (5%)C$MIRR(%)Base Case Consensus forecast4,963196,727237,27419Copper Price-20US$3.90/lb Cu3,218154,807195,43316Copper Price+20US$5.86/lb Cu6,688238,632289,09922Gold Price-20US$2,618.08/oz3,625165,223195,53916Gold Price+20US$3,927.12/oz6,289228,222278,99622Metal Prices-20All metal prices1,708103,165142,99311Metal Prices+20All metal prices8,1182710,2333211,44426Initial CAPEX+20Variable per Scenario4,448166,222196,73216OPEX+20Variable per Scenario3,660165,438205,59116Scandium Oxide Price-40US$900/kg Sc2O3    6,49618Scandium Oxide Price+40US$2,100/kg Sc2O3    8,05020 MINERAL RESOURCE ESTIMATEDoubleview Gold Corp announced an update of the Mineral Resource estimate (MRE). This estimate followed the Micon International Ltd. (Micon) Mineral Resource estimate with an effective date of July 17, 2024. This MRE incorporates significant new data from the 2024 and 2025 exploration campaigns, with an effective date of February 4, 2026, and superseded the 2024 Micon estimate.Table 5: Hat MRE at a 0.2% CuEq Cut-Off Effective February 4, 2026Mineral Resource ClassificationTonnage(Mt)Average GradeMetal ContentCuEq(%)Cu(%)Au(g/t)Co(g/t)Ag(g/t)CuEq(Blb)Cu(Blb)Au(Moz)Co(Mlb)Ag(Moz)Measured2720.440.220.1876.260.372.611.111.4135.62.17Indicated3370.430.210.1976.810.393.211.311.8144.52.88Total M+I6090.430.210.1876.570.385.822.423.2280.15.05Inferred5030.410.180.1976.620.384.571.722.7766.24.19 Table 6: Hat MRE at a 0.2% CuEq Cut-Off as of February 4, 2026, Scandium Oxide ResourcesMineral Resource ClassificationTonnage(Mt)Sc Tonnage1(Mt)Average GradeSc (g/t)Metal ContentSc2O3 2 (t)Measured2723428.791,081Indicated3374228.761,334Total M+I6097628.772,415Inferred5036328.691,996 Notes: 1 Scandium tonnages represent 12.5% of the mineralized material by category, reflecting the proportion of tailings expected to be processed through a dedicated scandium leach circuit under current metallurgical design constraints.2 Scandium oxide metal content have been calculated using the metallurgical recovery of 72% and conversion factor from Sc to Sc2O3 of 1.534. Mineit's Qualified Person, Tomasz Wawruch, FAusIMM, completed the MRE, and has reviewed and approved the technical disclosure related to the MRE contained in this news release. Mr. Wawruch is a senior geology and mineral resource consultant independent of Doubleview. Mr. Gilles Arseneau, PhD., P.Geo., of ARSENEAU Consulting Services Inc., provided an independent review of this MRE.Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues.Inferred Mineral Resources are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as Mineral Reserves. The Mineral Resource Estimate was prepared in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum (CIM) Definition Standards for Mineral Resources and Mineral Reserves (2014), and CIM MRMR Best Practice Guidelines (2019).The effective date of the MRE is February 4, 2026.Metal contents have been calculated using the following metallurgical recovery factors: Cu = 85%, Au = 89%, Co = 78%, and Ag = 68%.Economic assumptions used include US4.80/lb Cu, US20.00/lb Co, US3,200/oz Au, US46/oz Ag, and a 2% NSR royalty.Mineral Resources are reported within optimized open pit constraints and 0.2% CuEq cut-off grade, based on a C7.93/t milled processing cost and C2.90/t milled general and administrative cost, with a mining cost of C3.01/t plus incremental mining cost increasing by C0.015/t for every bench below the reference level of 1,125 mRL.CuEq calculations do not include scandium. The formula used to calculate CuEq is: CuEq = [(((Ag × 46.0 × 0.68)/31.1035) + ((Au × 3200 × 0.89)/31.1035) + 0.0001 × (Co × 20.0 × 0.78 × 22.0462) + 0.0001 × (Cu × 4.8 × 22.0462 × 0.85))/(4.8 × 22.0462 × 0.85)], where all input variables are expressed in (ppm) and CuEq is expressed in percent (%).Rounding may result in minor variations between individual values and totals; such differences are not considered material to the MRE.Mineral Resource classification reflects the level of geological confidence and satisfies the uncertainty criteria appropriate for exploration and resource development. Additional drilling will be required to reduce uncertainty to the level expected for production planning. The MRE reflects the geological interpretation, drill-hole spacing, and estimation parameters available at the time of modelling. Any additional drilling is expected to influence the current outcome by improving confidence in the estimates and refining the geometry of the mineralized domains.The Mineral Resource results are presented in situ within the optimized pit. Mineralized material outside the pit has not been considered as a part of the current MRE tabulation. Calculations used metric units (metres, tonnes, g/t).A total of 97 diamond drill holes, comprising 49,548 m of core, were incorporated into the Mineral Resource Estimate. All drilling data used in the MRE were subject to standard QA/QC validation prior to inclusion.PROCESSING SCENARIOSThe PEA evaluates two processing scenarios: (A) a conventional Cu-Au-Ag-Co flotation concentrator at 120,000 t/d (42 Mt/a) with two recovery cases-A1 based on metallurgical testwork completed by Sepro Laboratories (Langley, BC) and A2 reflecting target/expected performance-and (B) a full circuit that retains the base flowsheet and adds a downstream hydrometallurgical scandium recovery circuit.The concentrator consists of crushing, grinding, flotation, concentrate handling, and tailings management, producing both a saleable approximately 25% Cu concentrate with co-product gold and by-product silver-cobalt credits and a pyrite concentrate enriched in cobalt; in the full-circuit case, the pyrite concentrate is roasted to generate sulphuric acid and a calcine that is then processed to recover cobalt, gold, silver, and copper; after stripping it will be precipitated as a sulphide to be admixed to the copper concentrate to improve grade, with the acid used to leach flotation tailings for scandium recovery, noting that the scandium circuit is a newer chemical process compared with the otherwise industry-standard flowsheet.Under A1 or A2 (Figure 1), the flowsheet produces a single saleable product-a copper concentrate with payable gold credits; the pyrite concentrate is not treated or marketed in this case and is only processed in B where the hydrometallurgical circuit enables recovery of cobalt (and additional Au-Ag) and supports the scandium circuit (Figure 2), which is planned to be constructed in a phased approach commencing in Year 3 of operations.Figure 1: Grinding and Flotation Flowsheet; Scenarios A1/A2 Report Copper Concentrate Only, while the Cobalt-Pyrite Flotation Stream Shown Is Included Only in Scenario BTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/289584_doubleview1.jpgFigure 2: Scenario B Hydrometallurgical Plant Block Flow Diagram, Showing Downstream Treatment of the Cobalt-Pyrite Stream and Flotation of Tailings to Recover Cobalt (and Au-Ag) and Scandium, Including Sulphuric Acid Generation to Support the Scandium CircuitTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/289584_94c53b19649fcaba_003full.jpgTable 7 summarizes the head grades, concentrate grades, and overall metallurgical recoveries from early testwork for the full circuit; A1 assumes only the reported recoveries to the Cu-Au concentrate, while the cobalt-pyrite concentrate and downstream recoveries are considered only in B.Early metallurgical testwork comprised metallurgical characterization studies under standard laboratory conditions to demonstrate metals recoverability for inclusion in the estimate of CuEq. No attempt was made to optimize flotation conditions, and more advanced flotation testwork was not undertaken. Consequently, the reported metallurgical recoveries are considered conservative, and it is reasonable to expect improvement with further testwork.A2, assumes improved copper and gold recoveries of 89% and 75%, respectively, reflecting expected performance from comparable Cu-Au porphyry flotation circuits following further optimization and testwork.Table 8 summarizes the recoveries assumption on each scenario.CAPITAL COST SUMMARYTable 9 presents the estimated capital cost breakdown for the three evaluated scenarios, separating initial CAPEX from sustaining CAPEX and reporting costs in C$M by major cost area (processing plant, mining, pre-stripping, infrastructure, tailings and water management, Indirects/EPCM, and contingency).Total initial CAPEX is estimated at C$3,552 million (A1), C$3,601 million (A2), and C$3,828 million (B), reflecting the higher processing plant scope and associated indirects/contingency in Scenario B.Total sustaining CAPEX is estimated at C$2,755 million (A1/A2) and C$4,006 million (B), with the increase in B driven primarily by the inclusion of the hydrometallurgical plant and scandium recovery circuit within sustaining capital, while mining, infrastructure, and tailings sustaining components remain broadly consistent across scenarios.OPERATING COST SUMMARYTable 10 summarizes the key operating cost and selling terms used in the PEA, reporting unit costs in C$/t moved, C$/t milled, and (where applicable) C$/kg of scandium oxide, together with concentrate transport and selling costs, TC/RC, and payability assumptions.Average site operating costs are estimated at C$16.22/t milled for Scenario A (concentrate-only) and C$21.92/t milled for B, with the increase in B driven by the addition of hydrometallurgical processing and acid generation (C$3.09/t milled) and scandium oxide processing costs (C$939.55/kg Sc₂O₃).On a payable metal basis, the study reports C1 cash costs of C$2.4/lb CuEq (A1), C$2.39/lb CuEq (A2), and C$2.89/lb CuEq (B) and AISC of C$2.79/lb CuEq (A1), C$2.78/lb CuEq (A2), and C$3.39/lb CuEq (B), reflecting the combined effects of recoveries, co-product/by-product credits, and the additional operating requirements of the full circuit.ECONOMIC RESULTSTable 11 summarizes the key economic assumptions and resulting financial metrics for Scenarios A1, A2, B, including the long-term price deck, cash flow generation, taxation, and discounted valuation at a 5% discount rate. Using an exchange rate of 1.37 CAD: 1.00 USD and long-term prices of US$4.88/lb Cu, US$3,272.60/oz Au, US$50.22/oz Ag, and US$19.57/lb Co (and US$1,500/kg Sc₂O₃ for B), the Project generates average annual EBITDA of C$886 million (A1), C$1,071 million (A2), and C$1,284 million (B). On a post-tax basis, NPV(5%) is estimated at C$4,963 million (A1), C$6,727 million (A2), and C$7,274 million (B) with corresponding post-tax IRRs of 19%, 23%, and 19%, and post-tax payback in Year 6 (A1), Year 5 (A2), and Year 7 (B). Total post-tax free cash flow is estimated at C$10,050 million (A1), C$12,961 million (A2), and C$15,437 million (B), reflecting the higher cash generation under the improved recovery case (A2) and the additional revenue streams in Scenario B, partially offset by the added capital and operating requirements of the hydrometallurgical and scandium circuits.SENSITIVITY ANALYSISSensitivity cases were evaluated for the key value drivers using after-tax NPV (5%) and after-tax IRR, including ±20% copper and gold prices, +20% initial capital, +20% operating costs and, for B, a ±40% scandium price sensitivity.Overall, the sensitivity analysis demonstrates that the Project's after-tax economics remain positive across the tested ranges, with the greatest variability in after-tax NPV(5%) and IRR driven by simultaneous changes in the overall metal price deck. Changes to copper and gold prices individually have a meaningful but smaller effect, while +20% initial CAPEX and +20% OPEX reduce value but do not eliminate Project attractiveness in any of the evaluated scenarios. Scenario B shows additional exposure to scandium oxide price, with after-tax NPV(5%) varying within a narrower range relative to the broader multi-metal price cases, indicating that scandium provides incremental upside while the base-case Cu-Au Project remains financially robust on its own.PERMITTING, RISKS, AND NEXT STEPSPermitting and EnvironmentalPermitting StatusThe permitting process will be supported by the continuation of environmental baseline studies, progression of engineering designs, and the initiation of socio-economic and cultural baseline studies.Due to the anticipated rate of resource extraction, it is expected that the Hat Project will be subject to both federal and provincial impact assessment pathways, so submission to both the Impact Assessment Agency of Canada (IAAC) and British Columbia Environmental Assessment Office (B.C. EAO) for their review is currently anticipated. Agency determination will decide the appropriate level of agency collaboration under the existing cooperation agreement for the Hat Project to acquire a provincial Environmental Assessment Certificate (EAC) and/or federal Decision Statement.The company will also submit a Joint Mines Act and Environmental Management Act Application through the B.C. Major Mines Office. Additional federal authorizations, including Fisheries Act approvals and compliance with Metal and Diamond Mines Effluent Regulations (MDMER), and applicable provincial permits will be obtained concurrently with other assessment and permitting steps. This will not only support protection of the immediate environment through the life of the Project but also respect the rights of First Nations and promote social and economic wellbeing for local communities.Tailings and Water ManagementThe Tailings Storage Facility (TSF) includes a perimeter dyke primarily constructed from compacted cycloned sand. This material will be sourced from the coarse underflow of tailings processed through an on-site cyclone plant. Using the centreline raise method, the dam is designed to be free-draining, lowering the phreatic surface to facilitate geotechnical stability. During operations, seepage from the TSF will be directed to the process plant as reclaim water. Upon closure, the supernatant pond will be drained, and the tailings and dam surfaces will be reclaimed with a granular trafficability layer, followed by a growth medium and native revegetation.The water management strategy prioritizes the reuse of site-impacted water, directing TSF water, contact water from the waste rock storage facilities, and open-pit dewatering to the process plant for use as make-up water.Key Risks and OpportunitiesProject-wideTailings Storage Facility:The location and geometry of the TSF are subject to refinement following geotechnical investigations of the potential site areas. Similarly, the anticipated availability of cycloned sand and the storage requirements for the facility may be adjusted once laboratory testing of the tailings is conducted.The integration of this future site-specific data presents a significant opportunity to optimize the TSF design.Mineral Processing:Limited metallurgical and comminution data introduce uncertainty in equipment sizing and operating cost inputs; however, early results indicate the ore should be amenable to conventional Cu-Au flotation, with potential upside from improved recoveries and reduced reagent consumption through optimization.The scandium circuit is less mature and is sensitive to acid economics and hydrometallurgical performance, but offers meaningful value upside if recoveries, product quality, and operating stability are confirmed at larger scale.Mine Design:Pit slope design criteria and mine scheduling are subject to elevated uncertainty due to the limited geotechnical database, including incomplete definition of structural controls, rock mass variability, and groundwater conditions. This creates downside risk to slope angles, strip ratio, and operating conditions if adverse structures or hydrogeology are encountered; however, it also provides a clear opportunity to materially improve design confidence and potentially optimize slope geometry, mine sequencing, and dewatering requirements through focused data acquisition and updated analyses.Capital Cost estimates:As a PEA-level estimate, capital costs remain subject to the inherent uncertainty of a preliminary design basis and limited engineering definition; however, significant effort was undertaken to develop the estimate using a defined scope, preliminary equipment sizing, and factored/benchmark-based costing with appropriate indirects and contingency. This work provides a credible foundation for decision-making at this stage while also highlighting clear opportunities to optimize capital intensity through further engineering definition, value engineering, and targeted trade-off studies (e.g., comminution configuration, tailings strategy, infrastructure/power, and construction execution approach).Scandium specific:Scandium provides strategic upside given its small, concentrated global supply base and the growing premium placed on secure, qualified supply, but it carries higher execution and commercial risk due to limited scale-up testwork (variability, impurity control, reagent intensity), added residue-management and permitting complexity, and uncertainty around product specifications, pricing, and customer qualification.Next StepsResource:The Company is advancing the Project toward Pre-Feasibility by upgrading confidence in the current Mineral Resource estimate and improving definition of mineralization within the proposed mine plan area. The program will prioritize infill drilling to support conversion of Inferred Resources to Indicated (and, where appropriate, Measured), together with step-out drilling to test extensions of known mineralization and provide improved geological continuity for next-stage mine design, scheduling, and economic evaluation.Waste facilities:Field investigations will be conducted at potential TSF and waste rock storage sites to characterize subsurface conditions and identify suitable borrow materials for construction. These efforts will be supported by site-specific geotechnical and geochemical characterization of the tailings and waste rock. These data sets will inform a TSF design update to a Pre-Feasibility Study (PFS) level of engineering, encompassing an optimized siting and technology trade-off study.Metallurgy:Complete a comprehensive metallurgical testwork program on representative samples including comminution testwork (Bond Work Index, abrasion index, and related grindability tests) and metallurgical variability + locked-cycle flotation testing to define an optimal process flowsheet, mass balance, and optimized reagent scheme, and to produce samples for concentrate dewatering and preliminary smelter marketing.Progress the scandium work through targeted hydrometallurgical optimization including pulp density, free acidity/acid consumption, SX staging and extractant concentration, followed by an integrated pilot trial on bulk samples to validate scandium recovery, product quality, and circuit operability.Mine Design:A phased geotechnical program is recommended that includes re-analysis of existing boreholes (re-logging and detailed structural mapping, including oriented-core interpretation where available), establishment of geotechnical domains, targeted drilling and field mapping to confirm discontinuity sets and persistence, and hydrogeological data collection to constrain pore pressures and inflows. These data will support updated kinematic assessments and slope design analyses, refinement of inter-ramp and overall slope angles, and improved inputs to mine planning, risk management measures, and capital/operating cost estimates.Capital Costs Estimation:As the Project advances to PFS, the estimate will be progressively refined by advancing engineering to a higher level of definition, updating quantities and vendor inputs for major equipment and packages, tightening indirects and construction productivity assumptions, and executing focused optimization and constructability reviews to reduce contingency and improve overall cost confidence.NI 43-101 DISCLOSURE, QUALIFIED PERSONS, AND CAUTIONARY STATEMENTSQualified PersonsThe scientific and technical information in this news release has been reviewed and approved by the following Qualified Persons, each with respect to the matters within their area of expertise, (as defined under NI 43-101):Tomasz Wawruch, FAusIMM, Senior Geology and Mineral Resource Consultant of Mineit Consulting Inc. (responsible for the Mineral Resource estimate).Andrew Carter, EUR ING, B.Sc., CEng., MIMMM (QMR), MSAIMM, SME, of Magister Metallurgy (responsible for metallurgical studies and recovery processes).Shervin Teymouri, P.Eng., Mining Engineer of Mineit Consulting Inc. (responsible for project management, mining engineering, capital and operating cost estimates, and financial analysis).Andre de Ruijter, P.Eng., of Mineit Consulting Inc, (process design, process capital and operating cost lead).Franky Li, P.Eng., of EMM Consulting Pty Ltd (responsible for tailings management and TSF design, tailings capital and operating cost).Jayesh Rami, P.Eng., Infrastructure Engineer of Sacre-Davey Engineering Inc. (responsible for project infrastructure).Qualified Person ReviewThe scientific and technical information contained in this news release has been reviewed and approved by Shervin Teymouri, P.Eng., a Qualified Person as defined under National Instrument 43-101. Mr. Teymouri is a mining engineer and is independent of the Company.Preliminary Economic Assessment Cautionary StatementThe Preliminary Economic Assessment (PEA) for the Hat Project is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as Mineral Reserves. Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability. The PEA provides a conceptual mine plan and is based on low-level technical and economic assessments that are insufficient to support an evaluation of the economic viability of the Project or to establish Mineral Reserves. There is no certainty that the results of the PEA will be realized. Further exploration and site-specific engineering studies are required before a higher level of confidence can be established for the Project's economics.The economic analysis in the PEA is based on several assumptions including, but not limited to, long-term metal prices, foreign exchange rates, metallurgical recoveries, and capital and operating cost estimates. These assumptions are subject to significant risks and uncertainties, and actual results may differ materially from those projected. Readers are cautioned not to place undue reliance on the PEA or the forward-looking information contained in this release.Forward-Looking InformationCertain of the statements made and information contained herein may constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Often, these forward-looking statements can be identified using words such as "anticipates," "believes," "continue," "estimates," "expects," "forecasts," "intends," "plans," "projected," or the negatives thereof or variations of such words and phrases. Forward-looking statements in this news release include, but are not limited to, statements with respect to: the results of the Preliminary Economic Assessment for the Hat Project; the estimation of mineral resources; anticipated annual production of copper, gold, cobalt, and scandium; the after-tax NPV and IRR of the Project; forecasted AISC and Total Cash Costs; estimated initial and sustaining capital costs; the timing of a Pre-Feasibility Study; the timeline for permitting milestones and construction decisions; planned early works and infrastructure upgrades; and the Company's ability to maintain strong community and First Nations partnerships.Forward-looking statements are based on a number of assumptions that management considers reasonable at the time they are made, including assumptions regarding: the future prices of copper, gold, cobalt, and scandium; foreign exchange rates; metallurgical recoveries; the cost of essential consumables; and the geopolitical and regulatory climate in British Columbia. However, such statements involve known and unknown risks and uncertainties which may cause actual results to differ materially. These risks include but are not limited to inaccurate estimation of mineral resources; volatility in metal prices; the results of future exploration and development activities; liquidity and financing risks; failure to obtain necessary permits; geotechnical conditions; and changes in applicable mining laws. The PEA is preliminary in nature and includes Inferred mineral resources that are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as mineral reserves. Except as required by law, the Company undertakes no obligation to update or revise forward-looking information as conditions change.Non-GAAP Financial MeasuresThe Company has included certain performance measures in this news release that are not specified, defined, or determined under Generally Accepted Accounting Principles (GAAP). These non-GAAP measures are common in the mining industry but do not have standardized definitions and may not be comparable to similar measures presented by other issuers. Readers should not consider these measures in isolation or as a substitute for performance measures prepared in accordance with GAAP.Total Cash Costs: The Company calculates total cash costs as the sum of mining, processing, refining and transport, G&A, and royalty costs. Cash costs per unit are calculated by dividing the total cash costs by the payable Copper Equivalent (CuEq) units.All-In Sustaining Cost: AISC is a non-GAAP financial measure comprising of total cash costs, sustaining capital expenditures to support ongoing operations, and closure costs. AISC per unit is calculated by dividing the total all-in sustaining costs by the payable CuEq units.Sustaining Capital: This is a supplementary financial measure reflecting cash-basis expenditures expected to maintain operations and sustain production levels over the life of the mine.About Doubleview Gold Corp.Doubleview Gold Corp., a mineral resource exploration and development company based in Vancouver, British Columbia, Canada, is publicly traded on the TSX Venture Exchange (TSXV: DBG), the OTCQB (DBLVF), the Berlin Stock Exchange (GER: A1W038), and the Frankfurt Stock Exchange (1D4). Doubleview identifies, acquires, and finances precious and base metal exploration projects in North America, particularly in British Columbia. The Company increases shareholder value through the acquisition and exploration of quality gold, copper, cobalt, scandium, and silver properties-collectively critical minerals-and through the application of advanced, state-of-the-art exploration methods. Doubleview's portfolio of strategic properties provides diversification and mitigates investment risk.About Mineit Consulting Inc.Mineit Consulting Inc. (Mineit) is an independent mining engineering consulting company providing specialized expertise in project management, geological modelling, Mineral Resource estimation, mining engineering, metallurgical, and process engineering. Mineit led and prepared the Hat Project MRE and PEA, with assistance from other engineering firms, for the Hat Project in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum (CIM) Definition Standards on Mineral Resources and Reserves.For further information, please contact:Doubleview Gold CorpVancouver, BCFarshad ShirvaniPresident & CEOInstitutional Line: (604) 607-5470T: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Certain of the statements made and information contained herein may constitute "forward-looking information." In particular references to the Mineral Resource Estimate and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289584 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-23

在 2026 年 Gartner(R)《供應鏈規劃解決方案：流程工業》魔力象限(TM) 報告中，OMP 在「願景完整性」與「執行能力」兩大指標上均位居首位

比利時安特衛普, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - 這是該公司第11次獲評為「領導者」。OMP 認為，此項殊榮彰顯了其持續提供創新解決方案（如 UnisonIQ 和 Unison 決策導向規劃）的實力。這反映了市場正朝向 AI 驅動的供應鏈規劃轉變，以及市場對能即時整合策略、執行與智慧的平台的日益增長的需求。為最複雜的供應鏈需求推動智慧規劃OMP 獲得阿斯特捷利康、巴斯夫、強生及寶潔等《財星》500 強企業的信賴，並持續透過其經實證的端到端平台 Unison Planning™，推動供應鏈規劃的進展。該平台具備開放、雲原生及 AI 驅動的特性，專為滿足流程型與離散型全球供應鏈的演變需求而打造，涵蓋化學品、消費品、生命科學、紙張與包裝、輪胎與建築材料，以及金屬等產業。Unison Planning™ 整合了 OMP 的 AI 協調器 UnisonIQ，將 AI 代理、助理與引擎統一於一個強大的框架之中。UnisonIQ 專為供應鏈規劃的「代理時代」而設計，將持續性智慧嵌入整個平台，為企業奠定基礎，使其能基於深厚的產業專業知識，進行主動且自主的決策。「代理式 AI 正在從根本上重塑供應鏈的運作與競爭模式，」OMP 執行長 Paul Vanvuchelen 表示。「擁抱這項轉變的企業，將能將市場波動轉化為戰略優勢。」加速整個供應鏈的決策速度OMP 的 Unison 決策導向規劃（Unison Decision‑Centric Planning）透過整合人類專業知識、先進 AI、即時智慧及快速情境評估，提升供應鏈績效，從而推動企業整體的決策速度並改善決策品質。「憑藉全面的供應鏈智慧與 AI 驅動的預判能力，Unison 決策導向規劃能讓企業更早預見干擾因素、評估其影響，並以清晰且充滿信心的態度籌劃下一步行動，」OMP 首席商務與市場官 Philip Vervloesem 表示。關於 Gartner 魔力象限2026年3月發布的《2026年Gartner供應鏈規劃解決方案魔力象限：流程工業》報告，依據供應商的「執行能力」與「願景完整性」進行評估，協助全球企業在複雜且快速演變的市場中識別合適的合作夥伴。我們相信，這項認可與 OMP 在《2026 年 Gartner 流程工業供應鏈規劃解決方案關鍵能力報告》中的優異表現密不可分——該報告中，OMP 在所有應用場景中均名列前兩名。此外，OMP 在 Gartner Peer Insights™ 上持續獲得客戶的高度評價，反映出企業用戶的正面反饋。欲進一步了解 OMP 在 Gartner 魔力象限中的領導者地位以及供應鏈規劃的未來發展，請閱讀完整報告。於 Gartner 供應鏈研討會/博覽會™ 親臨 OMP 攤位OMP 將參與 2026 年 Gartner 供應鏈研討會/博覽會™，屆時客戶將分享關於智慧型、以決策為中心的供應鏈之實務見解：寶潔公司將在美國場次（Symposium/Xpo™ US）分享與 OMP 合作的重要經驗，重點闡述整合式規劃與端到端可視性如何帶來可量化的商業效益。阿斯特捷利康將在歐洲、中東及非洲場次（Symposium/Xpo™ EMEA）展示其邁向以決策為中心的自主規劃之旅，重點說明該公司如何透過轉型流程與能力以達成卓越表現。關於 OMPOMP 透過提供市場上最卓越的數位化供應鏈規劃解決方案，協助面臨複雜規劃挑戰的企業脫穎而出、成長並蓬勃發展。來自消費品、生命科學、化學、金屬、紙業、塑膠與包裝、輪胎及建築材料等廣泛產業的數百家客戶，皆因採用 OMP 獨有的 Unison Planning™ 而受益。Gartner，《供應鏈規劃解決方案魔力象限》，Pia Orup Lund、Joe Graham、Buse Aras、Jan Snoeckx、Eva Dawkins、Julia von Massow，2026年3月18日。Gartner，《供應鏈規劃解決方案關鍵能力：流程工業》，Julia von Massow、Eva Dawkins、Jan Snoeckx、Buse Aras、Joe Graham、Pia Orup Lund，2026年3月18日。Gartner 及 Magic Quadrant 均為 Gartner, Inc. 及其關聯公司的商標。Gartner 並不認可其出版物中所提及的任何公司、供應商、產品或服務，亦不建議技術使用者僅選擇評級最高或其他獲特殊標示的供應商。Gartner 出版物反映的是 Gartner 商業與技術洞察組織的觀點，不應被視為事實陳述。Gartner 對本出版物不作任何明示或暗示的保證，包括任何適銷性或適用於特定目的的保證。Gartner Peer Insights 的內容包含個別終端使用者基於自身經驗所提出的意見，不應被視為事實陳述，亦不代表 Gartner 或其關聯公司的觀點。Gartner 不對本內容中所述的任何供應商、產品或服務予以背書，亦不就本內容的準確性或完整性作出任何明示或暗示的保證，包括任何適銷性或特定用途適用性的保證。解決方案與產品諮詢聯絡 OMP媒體諮詢Kira Perdue (Carabiner)消息來源：OMP Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-23

Wellgistics Health Inc. 簽署價值 1.05 億美元的意向書，以評估收購 Neuritek Therapeutics, Inc. 的可能性；該公司致力於開發治療神經系統及精神疾病的創新療法

坦帕, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - Wellgistics Health, Inc.（「Wellgistics」或「本公司」）（納斯達克代碼：WGRX）今日宣布，已簽署一份非獨家且不具約束力的意向書（「LOI」），以評估潛在收購專注於神經科學研究的機構Neuritek Therapeutics。若這項擬議的全股票交易得以完成，旨在透過擴展其核心技術驅動的藥品分銷及服務業務周邊能力，強化 Wellgistics 現有的營收型醫療保健平台。透過涵蓋處方藥配送、批發分銷及 AI 驅動的患者用藥解決方案的整合生態系統，Wellgistics 串聯了製造商、醫療服務提供者以及遍布全國的獨立藥房網絡。本公司認為，納入一家以研究為導向的組織，將能強化藥物開發與商業化之間的協同效應，使公司得以更早與製藥合作夥伴建立聯繫、提升產品管線的透明度，並創造額外的營收機會；同時透過更整合且具差異化的平台，提升長期股東價值。本交易仍須待盡職調查完成、最終協議的協商與簽署、各方董事會批准，以及其他慣常的交割條件達成後，方能生效。無法保證雙方將簽訂最終協議，亦無法保證擬議交易將按目前預期的條款完成，甚至可能無法完成。該意向書不具約束力，亦不強制任何一方完成擬議交易。任何潛在交易的範圍、結構及條款仍在評估中，並可能因持續進行的盡職調查及協商而發生重大變更。作為更廣泛成長策略的一部分，本公司亦正積極評估醫療保健及生命科學領域的其他戰略機會。這些機會可能包括收購、合作夥伴關係或其他戰略交易。無法保證任何此類舉措將最終促成交易完成。關於 Wellgistics Health, IncWellgistics Health 是一家快速擴張、以科技為驅動的醫療保健平台，定位於藥品分銷與患者獲藥管道的核心。本公司已建立一個涵蓋批發分銷、處方藥配送及人工智慧驅動的獲取解決方案的整合型高效能生態系統，直接串聯製藥廠商、醫療服務提供者及全國性的獨立藥局網絡。透過整合基礎設施、數據與智能自動化，Wellgistics 正執行一套資本效率高的營運模式，旨在於龐大且分散的醫療保健市場中搶佔顯著市佔率。本公司致力於拓展高毛利收入來源、深化與製造商的戰略合作關係，並在整個平台上推動營運槓桿效應。憑藉獨特的端到端服務方案與嚴謹的執行力，Wellgistics 已做好準備加速成長、提升獲利能見度，並為股東創造超乎預期的長期價值。關於 Neuritek Therapeutics Inc.Neuritek Therapeutics Inc. 開發了一種基於生物機制的次世代療法，旨在治療創傷後壓力症候群（PTSD）的根本成因。Neuritek 首款上市療法為口服活性脂肪酸酰胺水解酶 1 型（FAAH1）抑制劑，該酶負責代謝內源性大麻素（AEA），亦是首個針對 PTSD 機制的治療方案。 該公司由威廉·哈普沃斯（William Hapworth）醫學博士創立，他不僅是臨床研究的先驅，更是一位擁有逾 30 年臨床經驗的執業精神科醫師。欲了解更多資訊，請造訪 www.neuritek.com ，或透過 LinkedIn 加入討論：neuritek-therapeutics-inc前瞻性陳述本新聞稿包含符合《1995年私人證券訴訟改革法案》及其他適用聯邦證券法定義義的前瞻性陳述。這些前瞻性陳述包括但不限於：關於潛在收購 Neuritek Therapeutics, Inc.（「Neuritek」）之陳述，包括任何交易的預期架構、估值、時程及完成可能性；意向書之初步且非約束性性質；任何此類交易可能帶來的戰略、營運及財務效益； 本公司協商並簽訂最終協議之能力；本公司取得任何必要融資之能力；任何被收購業務之整合；以及本公司的整體成長策略與未來表現。前瞻性陳述可透過諸如「可能」、「可能」、「將會」、「應」、「預期」、「預估」、「相信」、「意圖」、「計劃」、「預測」、「估計」、「潛在」、 「機會」、「目標」、「預測」、「持續」、「將」及類似表述。此等前瞻性陳述係基於當前預期、假設及估計，並受重大風險與不確定性影響，其中許多因素超出本公司控制範圍。可能導致實際結果與預期存在重大差異的重要因素包括但不限於：各方未能簽訂最終協議的風險；意向書被終止或未能促成交易完成的風險；擬議估值及交易條款具初步性質所帶來的不確定性（此等內容可能發生重大變更）；未能以可接受條款取得所需融資或完全無法取得融資的風險； 任何交易預期效益未能實現的風險；將以研究為導向的組織整合至本公司現有業務所伴隨的風險；藥品或治療產品的開發、測試、監管批准及商業化相關風險，包括可能出現不利的臨床結果或延誤；監管及合規風險；以及本公司不時向美國證券交易委員會提交的文件中所述的其他風險與不確定性。前瞻性陳述僅反映其作出當日的狀況，不應過度依賴此類陳述。除適用法律要求外，本公司無義務更新或修訂任何前瞻性陳述。Wellgistics 媒體與投資者聯絡資訊媒體： media@wellgisticshealth.com 投資者關係： IR@wellgisticshealth.com 消息來源：Wellgistics Health, Inc. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-23

億勝生物科技2025全年業績穩健 收入升8.6%至18.14億港元 淨利潤升3.5%至3.18億港元 全年股息增加16.7%至每股14港仙

關鍵業績摘要：- 收入增長：收入同比增長8.6%至約18.14億港元- 淨利潤提升：得益於運營效率，淨利潤增長3.5%至3.18億港元- 末期股息：擬派末期股息每股0.07港元，2025年全年股息達每股0.14港元，較2024年全年股息的每股0.12港元大幅增加16.7%- 現金及現金等價物：7.83億港元（2024年12月31日：5.57億港元）研發里程碑：- NMPA批准：多劑量地誇磷索鈉滴眼液於2025年7月獲批；多劑量玻璃酸鈉滴眼液於2026年1月獲批在中國註冊和商業化。- BLA受理：貝伐珠單抗眼內注射液的生物製品許可申請（BLA）於2025年8月獲NMPA受理，標誌著重要的監管里程碑。商業發展：- 獨家代理（視方極）：獲得浙江視方極富馬酸依美斯汀滴眼液、鹽酸奧布卡因滴眼液的獨家代理權。- 獨家代理（Osteopore）：獲得Osteopore創新的牙科、正畸及頜面產品在中國內地、香港及澳門的獨家代理權。- 與鷹瞳科技合作：在中國實現眼底AI業務的聯合運營。- 與科赴戰略合作：在中國推廣及營銷科赴的消費者健康產品（雷諾考特(R)、美林(R)、泰諾林(R)）。- 國際創新加速器：與蘇州工業園區簽訂戰略合作諒解備忘錄，推出國際創新加速器。- 首個海外市場准入：貝復舒(R)通過特別採用程序成功引入新加坡國家眼科中心。知識產權與市場佈局：- 強大的知識產權組合：持有合共121份專利證書或授權書，包括91項發明專利、15項實用新型專利及15項外觀專利。- 廣泛的銷售網絡：產品覆蓋中國內地超14,600家醫院和醫療機構以及約2,600家藥房。獎項與榮譽：- 2025年廣東省製造業企業500強：表彰產業規模及綜合競爭力- 國家級製造業單項冠軍企業：確認在專業生物製藥領域的領先地位- 2025「金鯤鵬」中國財經價值榜－最具投資價值上市公司：突顯資本市場對增長潛力的認可- 參與2026年亞太眼科學會大會：展示主要眼科產品及在研管線，加強與區域眼科專業人士及機構的聯繫。香港, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - 億勝生物科技有限公司（「億勝生物」及其附屬公司「集團」；股份代號：1061.HK），一家領先的生物製藥企業，專注於研發、生產和銷售基因工程藥物重組牛鹼性成纖維細胞生長因子（「rb-bFGF」），今日公佈截至2025年12月31日止的強勁年度業績。集團收入同比增長8.6%至18.14億港元，利潤同比增長3.5%至3.18億港元。年內，億勝生物達成了多項監管里程碑，並通過戰略合作擴大了產品組合，同時成功將貝復舒(R)引入新加坡。這些成就彰顯了億勝對創新和卓越運營的承諾，持續推動收入和利潤的增長勢頭。旗艦生物藥推動多元化增長集團實現綜合營業額約18.14億港元，較2024年的約16.70億港元增長8.6%。相應地，集團溢利較2024年的約3.07億港元增長3.5%至約3.18億港元。集團的旗艦產品貝復舒(R)系列及貝復濟(R)系列持續帶動增長，佔總營業額的83.5%。眼科分部錄得營業額8.35億港元，同比大幅增長8.2%。其中，單劑量貝復舒(R)滴眼液憑藉無防腐劑設計及應用場景的持續拓展（覆蓋乾眼症治療及術後修復等多元領域）實現強勁銷售增長，貝復舒(R)眼用凝膠、適麗順(R)（卵磷脂絡合碘膠囊）和一系列不含防腐劑單劑量滴眼液（包括妥布黴素、左氧氟沙星、玻璃酸鈉、鹽酸莫西沙星及地誇磷索鈉滴眼液）亦作出持續貢獻。外科分部實現營業額8.96億港元，增長1.8%，主要受惠於貝復濟(R)系列產品在多個臨床科室的廣泛應用及其穩固的市場地位。同時，貝復濟(R)系列產品已獲多項臨床指南及專家共識支持，為未來適應症拓展及持續增長奠定基礎。此外，集團的Carisolv(R)齲齒凝膠、皮耐克可吸收性敷料、適可健雙層人工真皮修復材料等產品進一步增強並促進了外科業務的發展。值得注意的是，醫療保健及夥伴服務於截至2025年12月31日止年度錄得總營業額約8,290萬港元，較2024年大幅增長350%。增長主要來源於伢典醫生口腔護理產品、線上及線下醫療保健服務及CMO/CDMO服務等。穩健的財務基礎和股東回報集團維持穩健的財務狀況。截至2025年12月31日，集團錄得現金及現金等價物約7.83億港元。銀行借貸為3.26億港元，將在未來五年內按計劃償還。集團的資產負債比率為30.9%（2024年：28.8%），反映出集團具備嚴謹的財務管理能力和充足的流動性。董事會欣然建議派發末期股息每股普通股0.07港元。連同中期股息每股普通股0.07港元，2025年全年股息達到0.14港元，較2024年全年股息的0.12港元同比顯著增長16.7%，以彰顯集團致力於為股東創造價值的承諾。廣泛的產品組合及強大的研發管線支持持續增長集團業務由三個核心分部組成：眼科、外科（創傷護理及修復）以及醫療保健及夥伴服務分部。集團擁有六種於中國市場銷售的商業化生物製劑，統稱「bFGF系列」。其中三種bFGF系列為國家藥品監督管理局（「NMPA」）批准的國家一類新藥，五種被列入中國國家基本醫療保險、工傷保險和生育保險藥品目錄。此外，集團提供一系列商業化的不含防腐劑單劑量滴眼液，包括妥布黴素、左氧氟沙星、玻璃酸鈉、鹽酸莫西沙星及地誇磷索鈉滴眼液。集團進一步拓展其眼科產品組合，分別於2025年7月及2026年1月獲得NMPA批准多劑量地誇磷索鈉滴眼液及多劑量玻璃酸鈉滴眼液在中國註冊和商業化。新獲批產品聚焦於中國不斷增長的幹眼治療市場，以補充集團的貝復舒(R)眼表修復系列產品。外科方面，集團的Carisolv(R)齲齒凝膠及伢典醫生口腔護理產品，以及一系列產品及醫療器械（包括紫外線光療儀、皮耐克可吸收性敷料、Osteopore用於牙科手術的生物可吸收植入物（Osteomesh(R)及Osteoplug(R)）及其他用於近視防控的醫療器械），共同補充了集團的貝復濟(R)創傷修復系列產品。戰略性研發投資以把握新興市場機遇集團致力於務實地投資新產品及技術，以強化其產品及研發管線，使命是開發解決未滿足的臨床及商業需求的突破性的療法。2025年，研發總支出約為1.77億港元，佔營業額的9.8%，其中約1.39億港元已資本化。年內，集團醫用疤痕修復凝膠獲批NMPA二類醫療器械註冊證，將集團業務拓展至快速增長的高端傷口護理及醫療美容市場，解鎖新增長動力以推動長期發展。貝伐珠單抗眼內注射液（EB12-20145P）的全球三期臨床項目已成功完成了在中國、澳大利亞、歐盟國家及美國的患者入組，最後一名患者已完成最後一次訪視。其生物製品許可申請（BLA）已於2025年8月獲中國NMPA受理。為提升集團在亞洲眼科領域的影響力，並加速新產品的市場推出，集團參與了2026年亞太眼科學會（APAO）大會。該會議提供了一個絕佳平台，用以展示眼科解決方案、與區域臨床專家和合作夥伴交流，並為集團創新眼科產品的推出積聚動能，從而提升全球品牌影響力。集團持有121份專利證書或授權書，包括91項發明專利、15項實用新型專利及15項外觀專利。集團目前於珠海（中國）、波士頓（美國）、倫敦（英國）及新加坡設立多個研發基地。這些基地為集團開發新療法和招募全球人才提供支援。截至目前，集團共有18項研發計劃處於臨床前至臨床階段，其中數項眼科項目處於臨床階段，具體包括貝伐珠單抗眼內注射液、SkQ1滴眼液及環孢素滴眼液。透過市場擴張與合作拓寬商業覆蓋截至2025年12月31日，集團於中國設有47間地區銷售辦事處，並於新加坡設有戰略基地，以促進其產品進入東南亞市場。憑藉龐大的分銷網絡，集團的治療產品在中國各地的逾14,600家醫院及醫療機構以及約2,600家藥房開具處方，覆蓋了中國各地的主要城市。回顧年內，集團在國內外市場擴張方面取得了多項里程碑式的突破，解鎖了多維度的新增長動力。在海外市場，集團的旗艦產品貝復舒(R)通過特別採用程序成功引入新加坡國家眼科中心，標誌著該產品首次進入中國以外地區，為集團未來進軍東南亞及全球市場奠定了堅實基礎。在國內，集團年內達成了兩項具里程碑意義的戰略合作：與全球消費者健康領導企業科赴合作，利用集團在中國廣泛的全國性商業網絡，對科赴精選的消費者健康產品（包括雷諾考特(R)、美林(R)及泰諾林(R)）進行推廣、學術教育及營銷；以及與Osteopore簽訂獨家分銷協議，在中國內地、香港及澳門分銷其創新的牙科、正畸及頜面產品，標誌著集團戰略性進軍高潛力的口腔科市場。這些合作拓寬了集團醫療保健業務的版圖，並與其現有的眼科及再生醫學業務產生強大的協同效應。為推動現有及未來產品的可持續增長和擴張，集團一直不懈地進行投資，通過擴大其商業化產品的臨床適應症、增加中國較低線城市的患者可及性、開發補充銷售渠道，以及培育醫療科技電子平台以增強患者可及性，來提高其競爭力並拓寬覆蓋範圍。集團位於珠海高新區科技創新海岸的第二間工廠，建築面積約58,000平方米，用作研發、生產、辦公及宿舍，預計將於2026或2027年間完工。億勝生物主席嚴名熾先生表示：「2025年對億勝來說是具有里程碑意義的一年，貝復舒(R)成功引入新加坡，集團亦依託其核心產品、創新研發及戰略合作，實現穩健增長。未來，億勝將繼續致力於滿足未被滿足的臨床需求，推動集團長期發展。我们將主動、系統性地優化運營及銷售成本，以缓解增值税由3%上调至13%对2026财年利润带来的不利影响，同时保證集團發展規劃的穩步推進。」關於億勝生物（股票代碼﹕1061.hk）億勝生物是一間專注於研發、生產和銷售基因工程藥物b-bFGF的生物製藥企業，擁有包括貝復舒(R)、貝復濟(R)、貝復新(R)在內的六種基因工程藥物在中國上市銷售。此外，公司還擁有包含一系列不含防腐劑單劑量滴眼液和適麗順(R)卵磷脂絡合碘膠囊等的多元化產品組合，主要應用於眼科及皮膚科處方藥領域的創傷修復及疾病治療。這些產品在公司於中國的47個區域辦事處的支持下，在逾14,600家醫院進行營銷和銷售。依託自身在生長因子和抗體技術領域的研發平台，億勝生物在多個臨床階段擁有强大的項目管線，涵蓋廣泛的領域和適應症。網址: http://www.essexbio.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-23

雲頂新耀達成艾曲帕米鼻噴霧劑資產收購協議 強化心血管領域產品佈局

香港, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀宣佈與箕星藥業香港有限公司（以下簡稱「箕星藥業」）達成資產收購協議 (The Asset Purchase Agreement)，獲得艾曲帕米（Etripamil）鼻噴霧劑（擬定中文商品名：星必妥(R)）在大中華區的開發、商業化及產品地產化權益。此次合作是公司深化心血管領域戰略佈局的重要舉措，進一步豐富了公司的產品管線、增強協同效應，持續鞏固公司在心血管疾病領域的發展。根據協議，雲頂新耀將向箕星藥業支付3000萬美元（相當於約人民幣206,937,000元）首付款，以及最高不超過2000萬美元（相當於約人民幣137,958,000元）的開發裏程碑付款。作為本協議的一部分，雲頂新耀將獲得箕星藥業於2021年5月簽訂的許可協議及相關附屬協議項下的權利、權益、主張、職責、義務及責任（不包括雙方約定的部分除外責任）。艾曲帕米鼻噴霧劑是一款新型、速效的鈣離子通道阻滯劑，采用便攜式鼻噴霧劑給藥，起效迅速且耐受性良好，可居家自行使用，可及性高。該藥物於2025年12月獲得美國食品藥品監督管理局（FDA）批准（美國商品名：CARDAMYSTTM），成為30多年來首款且唯一獲批用於成人陣發性室上性心動過速（PSVT）急性症狀性發作的療法，開拓了PSVT治療新場景。患者可在無醫療監督的環境（如居家）自行給藥，實現對病情的主動掌控，使疾病管理從依賴急診幹預轉向更加主動的院外管理。此外，艾曲帕米鼻噴霧劑正開發用於伴有快速心室率反應的房顫（AFib-RVR）適應症，II期臨床研究已取得積極結果，並計劃推進III期臨床研究，未來有望進一步拓展至更廣泛患者人群。在中國，艾曲帕米鼻噴霧劑用於治療PSVT的新藥上市申請已於2025年1月17日獲中國國家藥品監督管理局（NMPA）正式受理，並預計於2026年第三季度獲批，有望為PSVT患者提供全新的治療選擇。PSVT是一種以突發突止為主要特征的心動過速臨床綜合征，發作時心率極快且節律規則，通常持續數分鐘至數小時，患者症狀明顯且恐懼感強。PSVT急性發作的治療缺乏安全、便捷、可在院外自行使用的快速終止藥物，使患者在發作期長期處於「被動等待」狀態，缺乏真正意義上的「按需自救」工具。據悉，在中國，每1000中約有2.3-4人患有PSVT，估計總患者人數為300-600萬。AFib-RVR的特征是心率不規則，紊亂且快速，呈漸進式發作且不易自行終止，容易反複持續。目前中國的房顫患病率1.6%，對應患者人數約2000萬，並隨老齡化加劇呈上升趨勢。PSVT與AFib-RVR都會增加患者的失控感和心理負擔。整體來看，PSVT及AFib-RVR患者人群規模超過2500萬人，臨床需求遠未得到滿足，亟需更便捷、更高效的治療選擇。臨床數據方面，此次艾曲帕米鼻噴霧劑獲中國NMPA新藥上市申請受理是基於艾曲帕米關鍵性III期 RAPID 研究和中國III期 JX02002 臨床研究所取得的數據結果。JX02002研究達到了方案預設的主要終點，治療期出現的不良事件（TEAEs）在艾曲帕米治療組和安慰劑組之間相當。艾曲帕米鼻噴霧劑獲FDA批准是基於一項紮實的臨床試驗項目所得出的結論，該項目共收集了來自超1,800名參與者、超2,000次PSVT發作的安全性數據。這包括成功的3期RAPID試驗，這是一項在全球範圍內開展的、隨機、雙盲、安慰劑對照研究，結果於2023年發表在《柳葉刀》雜志上。RAPID試驗達到了其主要終點：自行使用艾曲帕米的參與者（N=99）中有64%在30分鐘內從室上性心動過速轉為竇性心律，而安慰劑組（N=85）為31%（HR = 2.62; p<0.001），中位轉複時間為17分鐘（95% CI：13.4，26.5），而安慰劑組為54分鐘（95% CI：38.7，87.3）。 艾曲帕米鼻噴霧劑正開發用於AFib-RVR適應症。在國際多中心、隨機、安慰劑對照的II期 ReVeRA 研究中，艾曲帕米顯著且快速地降低了AFibRVR患者的心室率，達到了主要終點。接受艾曲帕米治療的患者中，心室率低於100 bpm的人數（58.3%）高於接受安慰劑治療的人數（4%）。安全性總體良好並與既往研究結果一致。從戰略層面看，此次交易亦被視為雲頂新耀落實「2030戰略」的重要一步。在 2030 戰略的指引下，公司通過聚焦「BD合作+自研」雙輪驅動模式加速發展，全面推進戰略性業務拓展與自主研發，不斷豐富管線與產品組合，推進全球研發體系建設，並依托成熟的商業化實力，持續提升在全球創新藥領域的綜合競爭力，為患者提供創新療法並創造長期可持續價值。雲頂新耀董事會主席吳以芳先生指出，此次與箕星藥業的合作標志著公司在心血管領域戰略佈局的重要進展，體現了雲頂新耀對戰略落地的持續踐行與承諾，並通過進一步完善產品組合、強化核心戰略能力，展示公司在戰略規劃與執行上的前瞻視野，彰顯雲頂新耀在全球創新藥領域的領先發展格局。雲頂新耀首席執行官羅永慶表示：「此次與箕星藥業達成艾曲帕米鼻噴霧劑的資產收購協議，是公司深耕心血管領域的關鍵一步，也是推進2030戰略過程中取得的重要進展。艾曲帕米鼻噴霧劑是目前唯一可居家自行用於PSVT以及AFib-RVR急性發作的藥物，中國患者存在巨大的未滿足臨床需求。未來，雲頂新耀將依托成熟的臨床開發能力與卓越的商業化平台，加快艾曲帕米鼻噴霧劑在中國的注冊與商業化，助力更多患者受益，並充分發揮其長期臨床與商業價值。」隨著艾曲帕米鼻噴霧劑在中國注冊及商業化進程的推進，公司有望進一步拓展在心血管領域的產品佈局。未來，雲頂新耀將依托成熟的臨床開發體系與商業化平台，加快創新資產的落地與價值釋放，持續推進2030戰略實施，為患者帶來更多創新治療選擇。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-23

同仁堂醫養（02667.HK）新股招股：尚在發展早期的中醫醫療龍頭股 估值幾何？

香港, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - 在中醫藥文化傳承創新發展的時代浪潮中，一家承載著350餘年曆史積澱的醫療集團正昂首闊步走向國際資本市場。北京同仁堂醫養投資股份有限公司（以下簡稱"同仁堂醫養"）於2026年3月20日正式啟動港股IPO招股，股票代碼為02667.HK，招股價範圍為7.30港元至8.30港元，中金公司擔任獨家保薦人，將於3月30日掛牌交易。憑借深厚的品牌底蘊、卓越的醫療服務能力和清晰的戰略布局，同仁堂醫養向全球投資者展示中國中醫醫療服務行業的無限潛力。本次全球發售H股總數為108,153,500股，其中香港公開發售10%，國際發售90%，基石投資占比46.15%，設置綠鞋。對港股投資者而言，這是一個值得注意的機會，中醫醫療服務賽道此前僅有固生堂，兩者模式在中醫細分賽道顯現出差異化，未來發展也各有側重，同仁堂醫養的加入將為投資者提供新的配置選擇。百年品牌背書，大流量的降維優勢作為中華老字號的傑出代表，"同仁堂"品牌始創於1669年，擁有超過350年的曆史傳承。這份厚重的文化積澱不僅代表著百年品質，更是國人心中標志化的民族品牌，也是其最寶貴的無形資產。招股書顯示，按2024年總門診人次及住院人次計，同仁堂醫養是中國非公立中醫院醫療服務行業中最大的中醫院集團，市場份額達1.7%。按2024年中醫醫療服務總收入計，公司以0.2%的市場份額在非公立中醫院醫療服務行業中排名第二。這一領先地位的確立，離不開"同仁堂"金字招牌的強大號召力。憑借深厚的客戶信任和業內公認的高質量中醫醫療服務及產品，公司以極具成本效益的方式吸引和留住大量客戶及醫療頂尖人才。2024年，公司銷售和分銷開支中的推廣費占總收入比例約為0.2%，遠低於行業平均水平，充分彰顯了品牌自帶的強大引流效應。這是百年品牌壁壘最直觀的量化體現，在獲客成本日益攀升的醫療服務行業，這一差距意味著巨大的利潤釋放空間。業績穩健增長，盈利能力持續攀升翻開同仁堂醫養的財務畫卷，一組組靚麗的數據勾勒出企業蓬勃發展的態勢：1.收入規模持續擴大： 2022年至2024年，公司總收入從9.11億元（人民幣，下同）增長至11.75億元，複合年增長率達13.6%。2025年前九個月，收入達8.58億元，持續穩健增長。其中，中醫醫療服務作為核心業務，貢獻了總收入的84%以上，展現出穩健的主業增長動力。2.盈利能力顯著增強： 2022年公司曾錄得淨虧損923萬元，但通過高效的整合運營和精細化管理，2023年迅速扭虧為盈，實現淨利潤4263萬元。2024年淨利潤進一步增至4620萬元，同比增長8.4%。若剔除上市開支等一次性因素，2024年經調整淨利潤達6173萬元，較2023年的4787萬元大幅增長29%，核心業務"造血"能力持續強化。3. 毛利穩步提升： 毛利從2022年的1.43億元增至2024年的2.22億元，複合年增長率高達24.8%，超過收入增速2倍，毛利率從2022年的15.7%提升至2024年的18.9%，盈利能力穩升，規模效應加速顯現。4. 現金流健康： 2024年現金轉化率達87.2%，有息債務占比僅11.56%，截至2025年9月持有現金2.25億元，資產負債表穩健。作為一家2019年版塊組建的企業，同仁堂醫養正處於"扭虧為盈→盈利加速"的關鍵拐點期。回顧固生堂的發展軌跡，2021年上市時也處於發展早期，此後三年收入和利潤CAGR分別高達19%和47%，股價從IPO至今已實現數倍漲幅。同仁堂醫養當前的發展階段與固生堂上市初期高度相似--盈利能力剛進入釋放通道，增長最快的階段可能尚未到來。分級診療網絡，三條增長曲線並行同仁堂醫養並未滿足於傳統醫療機構的單一模式，而是前瞻性地構建起覆蓋全國的分級中醫醫療服務網絡。截至最後實際可行日期，公司已擁有12家自有線下醫療機構及1家互聯網醫院，以及12家線下管理醫療機構，形成"連鎖醫院-基層醫療機構-互聯網醫院"三級聯動的完整生態。這一布局產生了顯著的協同效應。就診人次飆升：醫療網絡內總就診人次從2022年的132.1萬人次飆升至2024年的297.7萬人次，複合年增長率高達50.1%。2025年前九個月，就診人次已達253.6萬人次，同比增長21.5%。會員粘性強勁：會員累計人數從2022年底的43.6萬人增至2024年底的74.0萬人，複合年增長率達30.2%，截至2025年9月底進一步增至76.7萬人，顯示出強大的用戶粘性和品牌忠誠度。區域戰略清晰：公司以北京為戰略核心深入紮根，同時深耕長三角等經濟活躍地區。北京地區貢獻了近半數的收入，而浙江省作為公司拓展華東市場的橋頭堡，2024年中醫醫療服務收入達2.25億元，毛利率達22.6%，展現出強勁的區域增長潛力。根據信息，公司的擴張主要通過戰略收購、輕資產新建以及管理服務，是公司快速擴張的重要引擎。2022年，公司收購浙江"三溪堂"品牌下的醫療機構，成功切入長江三角洲地區市場。自收購以來，通過標准化管理和專業化運營整合，三溪堂保健院業績持續提升：2022年至2024年，收入由1.025億元增長到1.982億元，複合年增長率39.1%；門診人次由18.38萬增至38.23萬，複合年增長率約44.2%，充分驗證了公司強大的投後整合能力。2024年，公司進一步收購上海承志堂等機構，強化在長三角的業務布局。此外，其另一核心擴張戰略為向公立醫院提供管理服務，目前已在北京、貴州、新疆、陝西等省份合作十餘家醫療機構。未來募集資金也將加速這一模式的擴張布局，放大輕資產模式的利潤杠杆。根據招股書披露，公司即將在齊齊哈爾和北京順義開設自建院區，開始邁向中西醫結合和高端醫療布局。名醫資源匯聚，供應鏈精益管理中醫醫療服務，醫師是靈魂。同仁堂醫養深諳此道，持續打造高素質的中醫醫師團隊。截至最後實際可行日期：- 網絡內共有2,745名醫師加入並執業- 30名擁有國家級榮譽稱號的醫師，其中全國名中醫2名、全國老中醫藥專家學術經驗繼承工作指導老師13名、非物質文化遺產代表性傳承人5名- 擁有820名主任醫師或副主任醫師，占比近30%- 通過建立"名醫工作室"和師承教育體系，公司已孵化13個國家級或省級名醫學術傳承工作室，促進寶貴中醫學術理論和臨床經驗的代代傳承- 公司還設立同仁堂中醫學術咨詢專家委員會，涵蓋中醫腎病、婦科、內分泌、腫瘤等八大醫學專科，致力於中醫標准化和人才培養。"炮制雖繁必不敢省人工，品味雖貴必不敢減物力"--同仁堂的古訓在公司供應鏈管理中得到了完美詮釋。公司成立全資附屬公司北京通達，建立采購協同管理平臺，整合網絡內醫療機構的采購需求，實現規模經濟，增強議價能力。在質量管控方面，公司實施嚴格的供應商選擇標准和驗收流程，定期委托第三方機構進行隨機檢測。2023年的一次內部盲評中，北京同仁堂中醫醫院所使用的中藥飲片在北京多家知名中醫院中得分最高，充分證明了公司在質量管理方面的卓越表現。數智化賦能百年傳承，同仁堂擁抱AI浪潮公司於2020年成立同仁堂互聯網醫院，將傳統中醫診療與現代科技完美融合。客戶可享受線上預約、健康咨詢、複診診斷、電子處方等一站式服務，打破了時空限制，讓優質中醫醫療資源惠及更廣泛人群。截至最後實際可行日期，在互聯網醫院注冊的醫師累計提供超過84.9萬次在線咨詢，覆蓋全國各地。公司還與超過500家外部藥店建立合作關系，實現"線上診療+線下配送"的業務閉環，打造線上線下融合便捷服務體驗。同仁堂不僅是百年工藝的傳承者，更是數智化轉型的排頭兵，正通過與用友等戰略夥伴的深度合作，將AIoT、大數據等數字技術深植於業務的每一個細胞。傳統"經驗主義"正被"數據主義"取代，同仁堂構建了"全鏈智能"的質量溯源體系，為核心產品提供了數字化護城河。2026年1月，同仁堂與北京市經信局簽訂任務合同書，支持開展"人工智能中藥新藥開發平臺"，構建十萬級方劑數據庫，通過AI技術為中藥新藥開發裝上"智慧大腦"。同仁堂醫養作為大健康終端，未來有望借助AI技術打破傳統服務時空限制，通過搭建智能化健康管理平臺，整合線上線下資源，為用戶提供個性化的健康監測、養生指導與遠程康養服務，實現從"治已病"向"治未病"的智慧化躍遷。戰略藍圖清晰，估值空間可期發展階段紅利：中醫醫療在港股中仍屬於稀缺標的，公司當前處於盈利加速的早期階段，隨著業務進入規模化擴張期，其利潤釋放空間值得期待。品牌溢價尚未充分定價：三百年品牌帶來的巨大流量，意味著每年節省的營銷開支相當於數千萬元級別的"隱形利潤"。隨著收入規模擴大，品牌壁壘的經濟價值將進一步放大。管理服務的輕資產模式：管理服務板塊從2022年至2024年收入增長700%，毛利率超70%，是高確定性的利潤增長極。這條輕資產第二曲線若持續放量，將顯著改善公司整體的盈利結構和ROE。集團協同的生態價值：公司是同仁堂集團"制藥-零售-醫養"大健康閉環的關鍵一環，與其他成熟版塊相比，發展空間巨大，上市後將享受集團資源的持續輸入。這種生態協同價值在當前估值中可能尚未被充分反映。隨著3月20日招股的正式啟動，同仁堂醫養正以紮實的業績、清晰的戰略和廣闊的前景，向全球投資者展示中國中醫醫療服務行業的無限魅力。正如其名，"醫"與"養"的完美融合，不僅呵護著萬千民眾的生命健康，更將開創中醫醫療服務的新紀元。轉載自格隆匯 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-23

From SGD to Global Spending: How Singaporeans Can Avoid FX Fees While Travelling Overseas

SINGAPORE, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Travelling overseas is exciting, but foreign exchange (FX) fees can quietly add up and increase your overall trip expenses. Many Singaporeans are now exploring smarter ways to manage overseas spending, and a multi-currency debit card can help reduce unnecessary FX charges while shopping, dining, and booking activities abroad. Whether you are heading to Japan, Australia, Europe, or the US, understanding how FX fees work can help you stretch your Singapore dollars further. Even a 3% fee on a SGD 5,000 trip translates to SGD 150, which could easily cover a nice meal or attraction tickets.When spending overseas, banks typically apply a currency conversion spread and may also charge overseas transaction fees ranging between 2.5% and 3.5%. On top of that, dynamic currency conversion at merchants can add another 4-8% markup. These layered charges might not be obvious at checkout, but they can significantly increase your travel budget.With a bit of planning and the right payment tools, Singaporeans can minimise these costs and enjoy more transparent spending abroad.Understanding Where FX Fees Come FromBefore looking at solutions, it helps to understand how FX fees are structured. Most traditional credit and debit cards issued in Singapore apply a foreign transaction fee when you pay in a currency other than SGD. This fee usually combines the card network's conversion rate and an additional bank administrative charge.For example, if you spend the equivalent of SGD 1,000 in Bangkok or Seoul, a 3% fee adds around SGD 30 to your statement. Over a 10-day trip with shopping and dining expenses of SGD 4,000, total FX charges could reach SGD 120 or more. These amounts may seem small per transaction but can accumulate quickly across hotels, theme parks, transport passes, and shopping malls.How a Multi-Currency Debit Card Can HelpA multi-currency debit card allows users to hold and spend multiple foreign currencies directly from one account. Instead of converting SGD at the point of sale for every purchase, you can preload currencies such as USD, EUR, JPY, or AUD in advance. This setup can help reduce conversion fees and give you more control over exchange rates.For instance, if you are travelling to Japan and expect to spend the equivalent of SGD 3,000, you can convert SGD to JPY when rates are favourable before departure. If the exchange rate improves even by 1%, that difference could mean savings of around SGD 30 on your total spend.Many multi-currency debit cards also offer competitive interbank or near-interbank rates with low or zero foreign transaction fees. While terms vary by provider, this structure may result in lower overall costs compared to traditional cards. Additionally, you can track balances in different currencies via mobile apps, which helps you manage budgets more clearly during travel.Practical Ways Singaporeans Can Reduce FX ChargesBeyond choosing the right card, several practical habits can help minimise FX fees while shopping overseas.Pay in the local currency whenever possibleWhen a payment terminal offers the option to pay in SGD or the local currency, selecting the local currency can help you avoid dynamic currency conversion markups. Merchants may apply rates that are 4-8% higher than market rates when you choose SGD. On a SGD 2,000 shopping bill in Seoul, that difference could translate to an extra SGD 80 or more. Paying in the local currency often results in a more transparent rate from your bank or card provider.Plan large purchases in advanceIf you are considering buying luxury goods in Europe or electronics in Japan, estimating your total spend beforehand can help you prepare accordingly. Planning major purchases can also help you avoid last-minute conversions at less competitive airport rates.Avoid exchanging large sums at airportsAirport money changers often offer less competitive exchange rates compared to city money changers in Singapore or digital FX platforms. The difference might range from 1% to 3%. On SGD 2,000 exchanged at the airport, this gap could mean paying SGD 20 to SGD 60 more than necessary. Using a multi-currency debit card for most transactions can reduce the need to carry large amounts of cash.Monitor overseas ATM withdrawal feesWithdrawing cash overseas may involve both local ATM fees and your bank's overseas withdrawal charges. These combined costs can range between SGD 5 and SGD 15 per withdrawal, excluding FX spreads. Planning fewer, slightly larger withdrawals, or relying more on card payments, can help reduce repeated charges. Some multi-currency debit cards may offer more competitive ATM withdrawal terms, depending on the provider.Comparing Travel Spending OptionsCredit cards may offer travel rewards but often carry foreign transaction fees of around 3%. Using cash helps you to do away with card fees but requires you to exchange money upfront, sometimes at less competitive rates.A multi-currency debit card sits somewhere in between, combining digital convenience with potentially lower FX costs, while offering more flexibility. For frequent travellers visiting destinations like Malaysia, Thailand, Japan, Australia, or the US several times a year, this flexibility can make budgeting more predictable.Avoiding FX fees does not require complex strategies. Small adjustments in how you pay, when you convert currency, and which card you use can collectively reduce costs. While exchange rates fluctuate and fees vary across providers, informed decisions can help you minimise hidden charges and make the best of your overseas trips.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-23

中國新城鎮2025年內溢利大增35.5% 持續派息回饋股東

香港, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - 2026年3月20日，專注於中國內地投資及優質資產持有運營的中國新城鎮發展有限公司（「中國新城鎮」或「公司」，及其附屬公司，統稱「集團」；香港股票代號：01278.HK）欣然宣佈截至2025年12月31日止12個月（「2025年」或「回顧期」）之經營業績。回顧期內，集團持續深化改革轉型路徑，在攻堅克難中交出高質量答卷。2025年集團錄得主營業收入約3.89億元（單位：人民幣，下同），同比增長15%；年內溢利7571萬元，同比增長35.5%；母公司權益擁有人應占溢利總額約7329萬元，同比增長65.4%。董事會建議派發末期股息為每股普通股0.0025港元。主營業務穩健增長，固收業務持續優化回顧期內，集團繼續保持穩健經營。2025年公司實現城鎮化投資收入2.31億元，同比增長約25%，主要因為城鎮化項目投資餘額較去年同期增加，對應項目投資收入增加。實現物業租賃及管理費收入人民幣約1.00億元，包括物業租賃收入人民幣0.76億元、物業管理費收入人民幣0.24億元。實現工程建設收入人民幣5,717.5萬元。面對國內外複雜經濟形勢，集團依託股東無錫交通集團與國開金融的資源優勢，充分發揮「地方國資+央企金融機構」的業務網路效應，做好主營業務的管理及運營，實現了穩定增長。2025年集團城鎮化投資業務穩中有進，持續貢獻穩定現金流。截至2025年12月31日，固定收益投資組合總額達人民幣33.66億元。優質資產運營穩中提質。武漢光穀物業項目面對市場壓力實現「止跌回升」，通過精准招商與服務升級，年底平均出租率回升至75%，保證了投資性房地產估值的穩定。借力股東資源聚焦戰略轉型，拓展增長新空間2025年集團緊抓國家大力發展新質生產力的政策機遇，結合股東的資源優勢，圍繞積體電路、新能源、新材料、高端裝備製造、環保等新經濟方向進行優質股權項目儲備，戰略並購路徑逐步聚焦及清晰，擬通過持有不同行業的優質資產，打造穩健收入及現金流以及後續新業務領域的增長空間。值得一提的是，集團發揮股東協同優勢，在實現經營業績穩健增長的同時，融資工作取得重大突破，成功發行15億元離岸人民幣債券，用於現有債務的再融資，進一步降低了債務成本並優化了期限結構，為集團後續業務的發展提供可持續的資金支援。持續派息，提供穩定股東回報2025年集團擬派發末期股息0.0025港幣/股，加上中期已經派發的中期股息0.0016港幣/股，2025年集團全年派息金額約3900萬港元。自2023年中期恢復派息以來，集團累計已經派發及擬派發股息金額達到了約1.2億元人民幣，顯示了持續回報股東的意願和行動。未來展望展望2026年，作為「十五五」開局之年，集團將緊扣國家新質生產力導向，聚焦戰略新興產業與信創產業，加速業務轉型。固收業務穩中提質，保障現金流；優化武漢光穀等核心資產運營，提升效能。同時，積極儲備優質股權項目，力爭戰略並購實質突破，持續為股東創造核心價值。關於中國新城鎮發展有限公司中國新城鎮（香港聯交所股份代號︰1278）為中國內地的投資及優質資產運營商。自2014年起，本集團順應中國新城鎮化發展趨勢優化了業務模式，以「投資+下游產品運營」的業務模式，通過固定收益類項目投資作為出發點，持有優質資產管理及運營，同時以市場為導向，全力在新材料、半導體、高端裝備製造等新經濟領域拓展股權投資業務，積累行業投資經驗。本新聞稿由千里國際顧問有限公司代表中國新城鎮發展有限公司發佈。如有垂詢，請聯絡：中國新城鎮發展有限公司 ir@china-newtown.com千里國際顧問有限公司Fancy Wang fancywang@maxima.hk Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-23

宇樹科技IPO點燃具身智能行情 首程控股（0697.HK）迎來「投資兌現+平台重估」雙重催化

香港, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - 人形機器人賽道再迎里程碑事件。3月20日，上交所官網顯示，宇樹科技股份有限公司科創板 IPO 申請已獲受理，融資金額 42.02 億元（人民幣，下同），審核狀態為「已受理」。這意味著宇樹科技正式向「A股人形機器人第一股」發起衝刺，也標誌著具身智能產業開始從主題催化邁向資本化兌現的新階段。從公開披露看，宇樹科技此次 IPO 並非單純的概念升溫，而是建立在業績高增長與產能擴張預期之上。根據公司招股說明書透露，公司 2025 年實現營業收入 17.08 億元，同比增長 335.36%；扣非後淨利潤超過 6 億元，同比增長 674.29%；公開發行新股不低於 4044.64 萬股，佔發行後總股本比例不低於 10%。對資本市場而言，宇樹科技最重要的意義，是開始提供一個更清晰的人形機器人估值參照系。公開報導顯示，宇樹科技在 2025 年初的估值約為 50 億元，到 2025 年 6 月已提升至約 120 億元；而本次招股書對應的初始發行後市值至少 420 億元，意味著其公開市場估值門檻較 2025 年中期的一級市場口徑又出現大幅躍升。對於資本市場而言，宇樹科技的上市進程則是釋放出一個清晰信號：人形機器人不再只是「技術想象力」的故事，而開始進入「收入、利潤、產能、融資」四線並進的新階段。對產業鏈而言，這將提升市場對整條賽道估值錨的清晰度；對已提前佈局頭部機器人的資本平台而言，則意味著賬面價值、退出預期與業務協同空間都有望同步抬升。在這一輪受益標的中，首程控股（0697.HK）的稀缺性尤為突出。公司在官方披露中明確表示，已通過北京機器人產業發展投資基金及旗下產業基金，投資宇樹科技、銀河通用、星海圖、松延動力等多家頭部企業；到 2025 年前三季度，其管理的多支產業基金又進一步完成了對宇樹科技、雲深處、加速進化、微分智飛、泉智博等核心機器人產業鏈公司的投資，覆蓋人形機器人、飛行機器人及上游關鍵環節。換言之，首程控股並非單點押注，而是在「頭部本体企業+上游關鍵環節+區域基金網絡」上形成了組合式佈局。更關鍵的是，首程控股的優勢不只在「投」，還在「投後賦能」。公司 2025 年中報和三季報均提到，其正圍繞「資金+場景+產業鏈」推進「投資+運營+生態」一體化路徑，並已設立北京首程機器人科技產業有限公司、首程機器人先進材料產業有限公司，拓展銷售代理、租賃、諮詢、供應鏈管理及上游材料延伸。同時，公司在首鋼園、北京首都國際機場 T3、成都春熙路等場景佈局常態化機器人體驗店和快閃店，推動機器人產品從展示走向商業落地。對於宇樹科技這類具備量產能力的明星企業而言，這種場景資源意味著更低的試錯成本和更快的商業驗證速度。這也是首程控股被市場視為「宇樹概念股」的核心原因：它不是單純二級市場「映射」，而是兼具資本紐帶、應用場景和產業服務能力的生態型平台。一旦宇樹科技 IPO 順利推進，首先受益的是首程控股機器人投資組合的市場認可度。頭部項目登陸資本市場後，外部投資者會更容易對首程控股存量未上市機器人資產進行對標估值。市場人士分析，從估值邏輯上看，宇樹科技 IPO 對首程控股至少構成三重利好：其一，首程控股的投資收益兌現預期抬升。 宇樹科技招股書顯示，「北京機器人產業基金」持有宇樹科技 3.8262% 股份，位列發行前前十大股東之一，而首程控股則是通過該機器人產業基金持有宇樹科技的股份。考慮新股發行稀釋後，這部分舊股對應的發行後持股比例約為 3.4436%。按 420 億元初始發行後市值測算，這一部分股權價值約為 14.46 億元；若對應 500 億元、600 億元上市後市值，則股權價值約分別為 17.22 億元和 20.66 億元，這將對首程控股現有估值體系形成邊際支撐。其二，是平台型估值中樞提升。 首程控股並非傳統意義上的單一財務投資者。公司主業一方面是基礎設施資產業務，另一方面是以基金和產業平台切入機器人、智能製造等新賽道。機器人賽道的公開市場估值錨形成後，首程控股整個機器人投資組合有望被整體重估。其三，是機器人生態商業化提速帶來的第二成長曲線。 過去市場給機器人概念股估值，往往停留在「參股收益」層面；但首程控股正在嘗試把機器人變成真實運營業務。公司披露已在線下體驗店、機場場景、文旅園區和智能停車等多個場景推進機器人落地，並與產業方合作推動「機器人+汽車」等新業態。若宇樹科技 IPO 後品牌效應和融資能力進一步增強，首程控股有望從「投中受益」擴展到「運營分成、渠道服務、場景服務、供應鏈協同」的多元受益。屆時，市場看待首程控股的框架，可能從「宇樹概念股」升級為「機器人生態基礎設施平台」。此外，首程控股的財務結構也為估值修復提供了安全邊際。公司 2024 年歸母溢利為 4.10 億港元，2025 年三季度末本公司擁有人應佔股本及儲備達 111.03 億港元，負債資本比率從 2024 年末的 15.9% 下降至 2025 年三季度的 10.9%。公司 2024 年度擬派末期股息 1.2 億港元，並在 2025 年還宣佈合共 7.68 億港元特別股息。較強的分紅意願、低槓桿與持續盈利能力，使其在「成長+收益」兩端都更容易獲得資金青睞。總體來看，宇樹科技 IPO 正式推上進程，是 2026 年具身智能產業最重要的資本事件之一。它不僅提高了頭部機器人企業的資本化確定性，也為首程控股這樣的生態型平台打開了價值重估窗口。隨著「明星項目上市—投資收益兌現—產業場景擴容—平台估值提升」邏輯逐步展開，首程控股有望成為本輪機器人行情中兼具安全邊際與彈性的核心受益者之一。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-23

Unitree Robotics IPO Ignites Embodied-Intelligence Rally, Shoucheng Holdings (0697.HK) Faces a Dual Catalyst of ‘Investment Realisation+Platform Re-Rating’

HONG KONG, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) -The humanoid robotics sector has reached another milestone. On 20 March, the Shanghai Stock Exchange confirmed that Unitree Robotics Co., Ltd. (operating entity: Hangzhou Yushu Technology Co., Ltd.) has received formal acceptance of its STAR Market IPO application, targeting proceeds of RMB 4.202 billion, with review status recorded as "Accepted". This marks Unitree Robotics' official push to become China's first A-share listed humanoid robot company, and signals that the embodied-intelligence industry is transitioning from a theme-driven narrative phase into a new stage of genuine capital-markets realisation.From publicly disclosed information, this IPO is not purely a concept re-rating event — it rests on a foundation of strong earnings growth and capacity expansion. According to the company's prospectus, Unitree Robotics generated revenue of RMB 1.708 billion in 2025, up 335.36% year-on-year; non-GAAP net profit exceeded RMB 600 million, up 674.29% year-on-year. The public offering involves a minimum of 40,446,434 new shares, representing at least 10% of the total post-IPO share count.For the capital markets, the most important contribution of Unitree Robotics is that it begins to provide a clearer public-market valuation reference for the humanoid-robotics sector. Reports indicate that Unitree's valuation stood at approximately RMB 5 billion in early 2025, rising to approximately RMB 12 billion by June 2025. The prospectus implies an initial post-IPO market capitalisation of at least RMB 42 billion — a dramatic leap from the mid-2025 private-market benchmark. For the capital markets, Unitree's listing trajectory carries a clear signal: humanoid robotics is no longer purely a story of "technological imagination" — it is entering a new phase of revenue, profit, capacity, and capital advancing on all four fronts simultaneously. For the supply chain, this raises the clarity of the sector's valuation anchor; for capital platforms that have invested early in leading robotics companies, it means book values, exit expectations, and business synergies all have room to rise in tandem.Among the beneficiary candidates in this cycle, Shoucheng Holdings Limited (HKEX: 0697.HK) stands out for its rarity value. The company has publicly confirmed that, through the Beijing Robotics Industry Development Investment Fund and its affiliated sub-funds, it has invested in Unitree Robotics, Galbot (Beijing Galaxy General Robot Co., Ltd.; X Square Robot , Noetix Robotics, and other leading enterprises. By Q3 2025, the multiple funds it manages had further completed investments in Unitree Robotics, DEEP Robotics / Hangzhou DEEP Robotics Co., Ltd.), Booster Robotics, Differential Robotics / Differential Robotics Technology Inc.), Wuxi Quanzhibo Technology Co., Ltd., and other core robotics supply-chain companies — covering humanoid robots, aerial robots, and critical upstream components. In short, Shoucheng Holdings is not a single-bet position, but a portfolio-style deployment spanning "leading robot OEMs + upstream critical components + regional fund networks."Crucially, Shoucheng Holdings' edge lies not only in "investing" but also in "post-investment value creation." Both the company's 2025 interim report and Q3 report highlight that it is advancing an integrated "Invest + Operate + Ecosystem" pathway centred on "capital + scenarios + supply chain." It has established Shoucheng Robot Technology Industry Co., Ltd. and Shoucheng Robot Advanced Materials Industry Co., Ltd., expanding into sales agency, leasing, consultancy, supply-chain management, and upstream materials. Simultaneously, the company has deployed permanent robot experience stores and pop-up stores at Shougang Park, Beijing Capital International Airport Terminal 3, and Chengdu Chunxi Road, accelerating the transition of robot products from showcase to commercial deployment. For high-volume producers like Unitree Robotics, these venue resources translate into lower trial-and-error costs and faster commercial validation cycles.This is also the core reason why the market treats Shoucheng Holdings as a premier Unitree Robotics proxy: it is not a simple secondary-market "reflection" play, but an ecosystem-type platform that combines capital linkages, application venues, and industrial service capabilities. Once Unitree Robotics' IPO advances smoothly, the first beneficiary will be the market recognition of Shoucheng Holdings' existing robotics investment portfolio. With a marquee portfolio company achieving public listing, external investors will find it far easier to mark-to-market the unlisted robotics assets still held by Shoucheng Holdings.Market analysts observe that, from a valuation standpoint, the Unitree Robotics IPO represents at least three distinct positive catalysts for Shoucheng Holdings.First, the anticipated realisation of investment returns has been significantly enhanced. Shoucheng Holdings holds 3.8262% of Unitree Robotics through the Beijing Robotics Industry Development Investment Fund, placing it among the top ten pre-IPO shareholders. After accounting for dilution from the new share issuance, the post-IPO stake corresponds to approximately 3.44%. Based on an assumed post-IPO market capitalisation of RMB 42 billion, this stake implies a value of approximately RMB 1.446 billion; at market caps of RMB 50 billion and RMB 60 billion, the implied values are approximately RMB 1.722 billion and RMB 2.066 billion respectively. Against the scale of Shoucheng Holdings' net asset base, these figures represent a material incremental contribution and will provide meaningful support to the company's existing valuation framework.Second, the platform-level valuation midpoint has scope to re-rate upward. Shoucheng Holdings is not a traditional single-strategy financial investor. Its core business encompasses infrastructure asset operations on one side, and entry into robotics and intelligent manufacturing through funds and an industrial platform on the other. Once the robotics sector has an established public-market valuation anchor, Shoucheng Holdings' entire robotics investment portfolio stands to be re-valued in aggregate.Third, the acceleration of robotics ecosystem commercialisation opens a genuine second growth curve. In the past, the market valued robotics concept stocks largely at the level of "equity participation income." But Shoucheng Holdings is actively working to transform robotics into a real operating business. The company has disclosed that it is advancing robot deployment across multiple scenarios — offline experience stores, airport environments, cultural-tourism parks, and smart car parks — and is collaborating with industry partners to develop new business formats such as "robotics + automotive." Should Unitree Robotics' brand recognition and fundraising capacity strengthen further post-IPO, Shoucheng Holdings could expand beyond "investment gains" to capture diversified value streams including operating profit-sharing, channel services, scenario services, and supply-chain coordination. At that point, the market's analytical framework for Shoucheng Holdings would graduate from "Unitree Robotics proxy" to "robotics ecosystem infrastructure platform."In addition, Shoucheng Holdings' financial structure provides a robust margin of safety for any valuation recovery. The company reported profit attributable to shareholders of HKD 410 million in 2024. Equity attributable to owners of the company stood at HKD 9.421 billion at end-2024. The gearing ratio declined from 15.9% at end-2024 to 10.9% by Q3 2025. In respect of the 2024 financial year, the company declared final dividend and special dividend totalling HKD 888 million, and together with the interim dividend of HKD 208 million, full-year distributions reached HKD 1.096 billion — exceeding 200% of the year's attributable profit. This combination of strong dividend commitment, low financial leverage, and sustained earnings power positions the stock favourably for capital flows seeking both "growth" and "income" attributes simultaneously.Taken as a whole, the formal advancement of the Unitree Robotics IPO process represents one of the most consequential capital-markets events of 2026 for the embodied-intelligence industry. It not only raises the capital-markets certainty for leading robotics companies, but also opens a valuation re-rating window for ecosystem-type platforms like Shoucheng Holdings Limited. As the logic of "flagship project listing → investment return realisation → industrial scenario expansion → platform valuation uplift" progressively unfolds, Shoucheng Holdings is well-positioned to emerge as one of the core beneficiaries of this robotics market cycle — a company that simultaneously offers a meaningful margin of safety and meaningful upside optionality. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-23

AEM and ASE Enter Strategic Partnership to Accelerate AI and HPC Test Innovation

Singapore and Taipei, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - AEM Holdings Ltd. (“AEM” or “the Group”), a global leader in test innovation, announced a strategic partnership with ASE Technology Holding Co., Ltd. (TWSE: 3711, NYSE: ASX) (“ASE”), the leading provider of semiconductor assembly, testing and materials (“ATM”) services and the provider of electronic manufacturing (“EMS”) services. The collaboration brings together AEM’s proprietary test technologies with ASE’s world-class manufacturing scale to deliver disruptive test solutions tailored for the rapidly expanding Artificial Intelligence (“AI”) and High-Performance Computing (“HPC”) markets.Aligned with the strategic partnership, AEM will raise approximately S$12 million in gross proceeds through a private placement of 3,350,000 million ordinary shares to a wholly owned subsidiary of ASE, representing 1.06% of AEM’s issued share capital as at 21 March 2026, at an issue price of S$3.591 per share. ASE, through said subsidiary, will also receive a total of 28,111,856 million free detachable warrants, divided equally into two exercisable tranches, with each tranche subject to certain ASE-attributable revenue-related conditions. Each warrant is exercisable into one ordinary share, with the Tranche 1 exercise price set at 103% of the volume weighted average price (“VWAP”) of AEM’s shares for the full market day on which the subscription agreement is signed, and the Tranche 2 exercise price set at 105% ofsuch VWAP. If fully exercised, the warrants would result in an additional 8.935% of the current issued share capital. The transaction remains subject to certain conditions, including the approval of the Singapore Exchange for the listing and quotation of the new shares.Proceeds from the private placement will support AEM’s continued expansion in Taiwan and the joint integration of AEM’s test technologies, including highly parallel test architectures and advanced thermal management capabilities, into ASE’s manufacturing and test environments. The funds will also be used to advance AEM’s product roadmap, enhance its system offerings, and accelerate joint go to market initiatives aimed at supporting next generation AI and HPC applications.The strategic partnership also supports ISE Labs, a wholly owned subsidiary of ASE, as it expands AI and HPC processor development capabilities to address early-stage testing, validation, and characterization requirements. These efforts focus on heterogeneous integration architectures, including multi-chiplet and advanced system-in-package designs as well as optical interconnect technologies critical to next-generation compute platforms. ASE’s ATM portfolio further strengthens these initiatives with high-volume advanced packaging and test capabilities, enabling production-scale deployment as global demand continues to accelerate.Ken Hsiang, Chief Executive Officer of ISE Labs, stated: “As compute architectures grow more complex and time-to-production continues to compress, test has become a critical enabler of performance, reliability, and manufacturability for next-generation AI and HPC systems. By combining ISE’s advanced characterization and production-readiness capabilities with AEM’s scalable, high-parallel test technologies and system-level engineering strengths, this strategic partnership enables rapid transition from validation to ASE’s high-volume deployment while addressing the increasing complexity of advanced compute testing.”Samer Kabbani, Chief Executive Officer of AEM, commented, “This partnership represents an important step in AEM’s strategy to work closely with industry leaders to advance the state of AI and HPC testing. ASE’s forward-looking approach and global scale make them an ideal partner as test requirements continue to intensify across advanced compute platforms. By combining our respective strengths, we aim to develop and deploy next-generation test solutions that help customers improve performance, scalability, and time-to-market.”About ASE Technology Holding Co., Ltd.ASEH is the leading provider of semiconductor manufacturing services in assembly and test. The Company develops and offers complete turnkey solutions covering front-end engineering test, wafer probing and final test, as well as packaging, materials and electronic manufacturing services through USI with superior technologies, breakthrough innovations, and advanced development programs. With advanced technological capabilities and a global presence spanning Taiwan, China, South Korea, Japan, Singapore, Malaysia, Philippines, Vietnam, Mexico, and Tunisia as well as the United States and Europe, ASEH has established a reputation for reliable, high quality products and services. For more information, please visit our website at https://www.aseglobal.com.About AEMAEM is a global leader in test innovation. We provide the most comprehensive semiconductor and electronics test solutions based on the best-in-class technologies, processes, and customer support. AEM has a global presence across Asia, Europe, and the United States. AEM's R&D centres are situated in Singapore, Malaysia, Finland, France, and the US. With manufacturing plants located in Singapore, Malaysia (Penang), Indonesia (Batam), Vietnam, Finland (Lieto), South Korea, and the United States and a global network of engineering support, sales offices, associates, and distributors, we offer our customers a robust and resilient ecosystem of test innovation and support.AEM Holdings Ltd. is listed on the main board of the Singapore Exchange (Reuters: AEM. SI; Bloomberg: AEM SP). AEM’s head office is in Singapore.For more information please contact:Kamal SAMUEL / Rishika TIWARI / LIM En Tong Financial PR Pte LtdTel: 6438 2990 / Fax: 6438 0064E-mail: kamal@financialpr.com.sg / rishika@financialpr.com.sg / entong@financialpr.com.sgPatricia MacLeod ASE, Inc.Tel: +1 408 314 9740E-mail: patricia.macleod@aseus.com Safe Harbor Notice (ASE)This press release contains "forward-looking statements" within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although these forward-looking statements, which may include statements regarding our future results of operations, financial condition or business prospects, are based on our own information and information from other sources we believe to be reliable, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to us, are intended to identify these forward-looking statements in this press release. These forward-looking statements are necessarily estimates reflecting the best judgment of our senior management and our actual results of operations, financial condition or business prospects may differ materially from those expressed or implied by the forward-looking statements for reasons including, among others, risks associated with cyclicality and market conditions in the semiconductor or electronic industry; changes in our regulatory environment, including our ability to comply with new or stricter environmental regulations and to resolve environmental liabilities; demand for the outsourced semiconductor packaging, testing and electronic manufacturing services we offer and for such outsourced services generally; the highly competitive semiconductor or manufacturing industry we are involved in; our ability to introduce new technologies in order to remain competitive; international business activities; our business strategy; our future expansion plans and capital expenditures; the strained relationship between the Republic of China and the People’s Republic of China; general economic and political conditions; the recent shift in United States trade policies; possible disruptions in commercial activities caused by natural or human-induced disasters; fluctuations in foreign currency exchange rates; and other factors. The announced results of the full year of 2025 are preliminary and subject to audit adjustments. For a discussion of these risks and other factors, please see the documents we file from time to time with the Securities and Exchange Commission, including the 2024 Annual Report on Form 20-F filed on March 27, 2025.Disclaimer (AEM)This is a press release of general information relating to the current activities of AEM Holdings Ltd. (“AEM”). It is given in summary form and does not purport to be complete. This press release may contain forward-looking statements which are subject to risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in these forward-looking statements as a result of a number of risks, uncertainties and assumptions. Representative examples of these factors include (without limitation) general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from other companies, shifts in customer demands, customers and partners, changes in operating expenses, governmental and public policy changes, and the continued availability of financing. Accordingly, such statements are not and should not be construed as a representation as to the future of AEM, and are not intended to be profit forecasts, estimations or projections of future performance and should not be regarded as such. No reliance should therefore be placed on these forward-looking statements, which are based on the current views of the management of AEM. The press release is also not to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. AEM accepts no responsibility whatsoever with respect to the use of this document or any part thereof. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-23

百年金字招牌煥新顏：同仁堂醫養啟動招股 四大投資邏輯錨定”中醫醫療服務龍頭”

香港, 2026年3月20日 - (亞太商訊 via SeaPRwire.com) - 北京同仁堂醫養投資股份有限公司（以下簡稱"同仁堂醫養"）在資本市場的聚光燈下宣布進行全球發售，中金公司擔任獨家保薦人，將於3月30日開始掛牌交易。根據公告內容，本次全球發售的H股總數為108,153,500股。其中，香港公開發售股分為10,815,500股，國際發售股分為97,338,000股，兩者均可予重新分配。此次沖刺意味著這個中藥老字號正通過資本紐帶，將自身沉澱了三百多年的品牌理念和中醫醫養延伸進更多場景和地區。走向港股市場後，同仁堂集團將補齊"制藥-零售-醫養"大健康生態圈的最後一塊拼圖。在萬億級中醫醫療服務賽道中，這個357年的金字招牌究竟值多少？厚積薄發：中醫醫療服務的領跑者同仁堂作為中國為數不多的擁有三百多年品牌曆史的民族企業，這塊金字招牌自2019年開始大步進軍中醫醫療服務賽道，致力於將傳統中醫藥精髓與現代醫療管理服務相結合。作為同仁堂集團唯一戰略性聚焦於中醫醫療服務的子公司，同仁堂醫養結合"醫療"與"養生"，通過標准化的連鎖經營以及現代化的管理系統，提供一站式定制化中醫醫療服務，綜合覆蓋全場景中醫診療需求，成為便捷可及的中醫健康專家。招股書顯示，同仁堂醫養的門診服務收入在中國非公立中醫院醫療服務行業的所有中醫集團中排名第一，是第二大醫院集團的2倍；其門診及住院人次在中國非公立中醫院醫療服務行業的所有中醫院集團中排名第一。按2024年總門診人次及住院人次計，同仁堂醫養是中國非公立中醫院醫療服務行業中最大的中醫院集團。該細分市場的規模已占同年中國中醫醫療服務行業總市場規模的46.5%。在這個極度分散、缺乏龍頭的中醫醫療服務市場，能夠拿下"頭把交椅"，本身就是同仁堂醫養百年品牌底蘊加持下厚積薄發的底氣， 而1.7%的市占率也意味著龍頭企業的整合空間才剛剛開始。四大投資邏輯：為什麼此刻值得關注邏輯一：業績已過驗證期，增長質量持續提升據悉，公司FY22-FY24年收入CAGR（年複合增長率）高達13.6%，FY22-FY24年毛利CAGR高達24.8%，毛利增速遠超營收增速，盈利結構持續優化，跑出了稀缺的增長質量。FY2024現金轉化率為87.2%，擁有非常強健的內部流動性，"賺到的利潤是真金白銀"。期間費用率從17.1%降至13.6%，三年下降3.47個百分點，規模效應加速兌現。 有息債務占比僅11.56%，經營性現金流持續淨流入，截至2025年9月現金2.25億元，具有充分的安全墊，已經進入"增長和盈利"正相關的良性循環。邏輯二：全產業鏈協同的"降維打擊"同仁堂醫養依托的是百年積澱所形成的產業壁壘--同仁堂集團深入中醫藥行業全產業鏈，擁有深度的產業鏈協同能力。其自建的醫療服務網絡覆蓋醫院、門診部及診所、社區醫療機構等，一旦與同仁堂遍布全國的藥診店相結合，其機構密度和服務能力將呈現指數級增長。據披露信息顯示，其已經開始於自建的互聯網醫院為線下藥房和醫師提供線上醫療服務，目前業務範圍覆蓋全國。此外，依托同仁堂集團資源，公司通過收購三溪堂國藥館以及獲得安宮牛黃丸系列產品在浙江區域的獨家零售權後銷量大增，公司健康產品和其他產品的銷量在整個往績記錄期間實現爆發式增長。依托這塊金字招牌，公司的推廣費用率僅0.2%，遠低於行業平均水平--別人花大價錢獲客，同仁堂天然自帶流量。正如市場分析人士指出，同仁堂的資本棋局，本質是通過專業化分拆實現精准發力。醫養板塊作為"最後一公裏"，不僅直接創造營收，更成為拉動同仁堂集團中藥產品銷售、增強用戶粘性的超級入口。同仁堂醫養上市後，同仁堂的"制藥-零售-醫養"三位一體的大健康生態圈將完整閉合。邏輯三：內生外延雙輪驅動，增長飛輪已形成如果說品牌和集團資源是"先天優勢"，那麼同仁堂醫養通過"內生+外延"構建起的服務網絡，則是其征戰資本市場的"後天壁壘"。同仁堂醫養已建立了一個分層級、廣覆蓋的中醫醫療服務網絡。據招股書顯示，公司擁有15家醫院，覆蓋北京市、浙江省、山西省、遼寧省、黑龍江省、貴州省、新疆維吾爾自治區；9家基層醫療機構，覆蓋北京市、浙江省、上海市，及1家互聯網醫院，形成了"線下首診+線上複診"的業務閉環。在擴張路徑上，公司采取"並購+自建+管理"多輪驅動模式。為了快速切入長三角經濟發達地區，公司相繼收購了浙江三溪堂、上海承志堂等當地知名機構，通過"品牌賦能+標准化管理"實現收購標的的快速整合與業績提升。根據信息，其以輕資產方式自建的方式在齊齊哈爾、北京順義等地的新機構即將開業，同時通過向非營利性醫療機構輸出管理經驗、醫師和人才、標准化的服務，同仁堂醫養正將"同仁堂標准"複制到更廣闊的市場。邏輯四：守正創新，AI+中醫打開想象空間中醫藥老字號的煥新，既要守住"正"，也要創造"新"。這一點，這一點在同仁堂系的各個板塊均有體現。2025年8月25日，公開報道顯示，同仁堂股份與小米商業營銷達成合作，推出"同仁堂養生館"AI智能中醫藥健康服務智能體，將中醫藥知識與AI交互能力結合，面向用戶提供個性化的養生建議、用藥指導與節氣調養方案，已經形成"咨詢-建議-服務-購藥"閉環。可見，通過引入AI智能問診與健康檢測設備，同仁堂正在推動自身從"被動賣藥"向"主動健康管理"轉型，讓百年藥鋪變身便民的"智慧健康服務站" 。作為同仁堂集團大健康版圖的關鍵一塊，同仁堂醫養不僅承載著老字號在醫療服務領域的創新探索，更以其清晰的分級診療布局、深厚的醫師資源及強大的產業協同效應，向資本市場講述了一個關於傳承與創新的長期主義敘事。此次赴港IPO，對於同仁堂醫養而言，既是機遇也是挑戰。作為擁有三百五十餘年曆史的中醫藥老字號，同仁堂不僅即將打通"中醫藥全產業鏈"的資本閉環，更將為老字號在AI經濟浪潮中探索出一條"智能中醫"的新路徑。百年金字招牌如何通過資本的力量再次煥發光彩，市場正拭目以待。轉載自財聯社 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-20

FILMART and EntertainmentPulse draw about 8,000 industry participants

HONG KONG, Mar 20, 2026 - (ACN Newswire via SeaPRwire.com) – The 30th Hong Kong International Film & TV Market (FILMART) and EntertainmentPulse, organised by the Hong Kong Trade Development Council (HKTDC), concluded successfully today. The two events attracted about 8,000 industry professionals from 53 countries and regions, highlighting the development momentum and collaborative potential of the global film and television industry. The events, held over four days, featured over 790 exhibitors across a record high participation of 38 countries and regions, bringing together enterprises from emerging markets like ASEAN members such as Cambodia, Malaysia, Thailand, and Vietnam, and mature film markets such as Canada, France, Italy, Korea, the United Kingdom, and the United States, further exemplifying Hong Kong’s position as a centre for cultural and artistic exchange.FILMART advances international collaboration in the film and television industryThis year’s FILMART continued to demonstrate its role as one of the region’s most influential film and television trading platforms, bringing together exhibitors, buyers and producers from both emerging and mature markets to facilitate cross-regional collaboration and business cooperations. Participating in FILMART for the first time, the General Manager of COL International Group, Timothy Oh from Singapore, noted that FILMART plays a key role in helping companies expand their international networks, he said: "I am meeting friends and new business partners from Turkey, the UK, the US, and even Brazil. Hong Kong’s role as an international hub helps create a bustling market with many business opportunities for those looking at innovation and what’s next.” Sachitha Kalingamudali, General Manager of another first-time exhibitor Mogo Studios from Sri Lanka, said FILMART exceeded his expectations. "We've met distributors from many countries, and everyone has shown genuine interest. This is a great kickstart for future partnerships." Myanmar film production company aTwentyThree even chose FILMART as its first move to explore the international market, founder Arker Soe Oo connected with distributors from the US and Europe, and expressed plans to bring more productions to the event next year.Overseas buyers also expressed strong recognition of the exhibition’s business matching effectiveness and the diversity of its content, further affirming that FILMART serves as an efficient platform for advancing collaboration across the global film and television value chain and strengthening market connectivity. Bizhan Tong, a buyer from the UK, commented: “FILMART continues to be one of the most effective platforms globally for driving cross-border collaboration. This year we formed a new strategic partnership with MOFAC, advanced multiple projects across both our and other companies' slates, and saw a highly concentrated run of meetings with partners across Asia translating into tangible co-investment and co-production opportunities.”AI Hub supports Mainland tech companies in going globalA highlight of this year’s FILMART was AI Hub which had multiple leading AI and technology companies showcasing their latest AI technologies and solutions, attracting buyers and potential partners from around the world for business discussions and exchanges. Through this platform, many Mainland start-ups and established enterprises have accelerated their expansion into overseas markets and built international networks, further enhancing brand visibility and converting opportunities into concrete business outcomes. Zhihan Zhang, Founder and CEO of Daogu Culture Limited, remarked, “Whether it is AI animation, short dramas, or digital humans, the key to the future lies in global strategy. FILMART gathers global industry professionals, facilities connections and exchanges, and enables us to understand the various client needs of different overseas markets.” In addition, the newly established "AI Academy", supported by the Cultural and Creative Industries Development Agency and the Film Development Fund, was well-received. 19 thematic workshops equipped industry professionals with hands-on AI skills and insights into emerging trends.Producers Connect fosters collaboration between local and global producersProducers Connect, jointly organised by the HKSAR’s Culture, Sports and Tourism Bureau, the Cultural and Creative Industries Development Agency, the Hong Kong Film Development Council and the HKTDC, united more than 100 producers from Hong Kong and around the world this year. Through a series of networking sessions, panel discussions and workshops, Producers Connect provided a cross-regional platform for creative collaboration, enabling industry professionals to share production trends, explore co-production models and discuss potential projects. The initiative strengthens connections between Hong Kong and the international film and television community, creating more possibilities for jointly expanding into the global market. Speaking at the panel discussion titled “International Coproductions in an Evolving Film Industry Landscape,” Janet Yang, Golden Globe-winning producer, observed: “The world is getting flatter, language is mattering less and less to audiences everywhere.” Producer and director Peter Chan also mentioned: “It’s always difficult to convince the studio, the investor, or now the platform, of a vision you want to make. What you try to do is diversify your investors and partners into different regions.”48 featured forums and events examine emerging industry trendsTwo major forums held alongside FILMART — EntertainmentPulse and the Digital Entertainment Summit — focused on the latest developments in the global film, television and entertainment technology sectors, attracting strong participation from industry professionals. EntertainmentPulse addressed popular topics including artificial intelligence, streaming platform strategies, the rising popularity of short dramas, co-production and financing trends. Industry leaders shared insights on global market strategies and future directions, helping the sector capture emerging opportunities. The Financing & Investment panel, themed “Capital in Motion: Private Financing Promotes Development of Asia’s Film & TV Industry,” explored Asian private investment trends, project financing strategies and planning. Justin Deimen, Managing Partner of Goldfinch International, shared: “We need to allocate more resources and capability towards creative IP valuation. If you cannot value something, you cannot invest in it.”Meanwhile, FILMART Online IP Catalogue featured more than 2,200 creative IP projects, extending the four-day physical fair into a two-month networking platform helping industry stakeholders continue exploring business opportunities. This initiative further consolidated Hong Kong’s position as Asia’s film and entertainment trading hub. The catalogue will remain open until 27 April, enabling industry participants to transcend geographical boundaries and continue expanding global business opportunities.Website:FILMART— http://www.hktdc.com/hkfilmartEntertainmentPulse—https://hkfilmart.hktdc.com/conference/hkfilmart/en/programme'category=EntertainmentPulsePhoto Download:  https://bit.ly/4sxPP6I    The 30th Hong Kong International Film & TV Market (FILMART) and the EntertainmentPulse, organised by the Hong Kong Trade Development Council (HKTDC), concluded successfully today. The two events attracted about 8,000 industry professionals from 53 countries and regions, highlighting the development momentum and collaborative potential of the global film and television industryThis year, FILMART welcomes the first-time participation of emerging markets including Belgium, Poland, Sri Lanka, Myanmar, and Uzbekistan; the picture shows the exhibitor from UzbekistanThe AI Hub displays the latest AI technologies and solutions, assisting Mainland tech companies take a crucial step in going globalProducers Connect’s panel discussion specially invited renowned director Peter Chan (second left) and Golden Globe Award-winning producer Janet Yang (second right) to attend, bringing new inspirations and directions for international co-productions to the industryEntertainmentPulse addresses a range of popular topics, including artificial intelligence, streaming platform strategies, the rising popularity of short dramas, co-production and financing trends. Industry leaders share insights on global market strategies and future directions, helping the sector capture emerging opportunitiesMedia enquiries:For enquiries, please contact:Raconteur PR:Betsy TseTel: (852)  9742 7338   Email: betsytse@raconteur.hkMolisa LauTel: (852)  6187 7786       Email: molisalau@raconteur.hkHKTDC Communication and Public Affairs Department:Serena Cheung      Tel: (852) 2584 4272Email: serena.hm.cheung@hktdc.orgHKTDC Mediaroom: http://mediaroom.hktdc.com/enAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-20

康哲藥業業績拐點確立：創新藥與獨家藥接棒增長 新藥進入密集兌現期

香港, 2026年3月20日 - (亞太商訊 via SeaPRwire.com) - 3月16日，康哲藥業（0867.HK）發佈2025年度業績公告，全面展現戰略轉型成效。財報顯示，公司業績已重回長周期增長軌道，創新藥與獨家藥成為核心增長引擎，集采影響基本出清，疊加多款重磅新藥密集獲批與管線穩步推進，長期發展動能全面煥新。憑藉紮實的基本面及穩步兌現的創新成果，康哲藥業2025全年公司股價累計上漲77.88%，清晰印證了市場對其創新實力的認可。2025年報亮點：業績重回增長軌道，創新研發矩陣擴容提質2025年是康哲藥業戰略轉型的關鍵收穫年。財報顯示，公司營業額同比增長9.9%至82.12億元（人民幣，下同）；若全按藥品銷售收入計算達93.86億元，同比增長8.9%；正常化年度溢利17.76億元，同比增長3.6%，標誌着公司已徹底消化集采負面影響，業績增長迎來拐點；毛利同比增長8.3%至58.72億元，毛利率維持在71.5%的較高水平，盈利質量穩固。在業績增長的同時，公司慷慨回饋股東，建議末期股息每股0.1366元，全年總股息達0.2921元/股，同比增長9.0%，彰顯對股東回報的重視與未來發展的信心。與此同時，康哲藥業的業務結構優化成效顯著，主要獨家/品牌產品及創新產品占藥品銷售收入比重升至59.8%，其中獨家藥和創新藥同比增速高達44.1%，成為驅動增長的核心引擎。研發管線方面，康哲藥業現已進入密集收穫期，形成上市放量、審評衝刺、臨床推進的梯次佈局。2025年以來，公司新增2款創新藥獲批上市，截至目前共有7款創新藥商業化，6款中國NDA審評中，約20項臨床開發有序推進。健康的產品梯隊，確保康哲藥業2026-2030年間每年都有新藥獲批上市，為中長期增長奠定堅實基礎。重磅新藥填補臨床空白，細分賽道治療格局有望重塑康哲藥業近期獲批的兩款重磅新藥，均精準瞄向臨床未被滿足的核心需求，有望在細分領域重塑競爭格局。2026年3月13日，德昔度司他片獲國家藥監局批准上市，作為創新型口服HIF-PHI，適用於非透析的成人CKD患者貧血治療。目前，我國CKD患者群體規模超1.2億，其中非透析患者貧血治療達標率僅8.2%，臨床未被滿足需求顯著。產品中國III期臨床試驗顯示，德昔度司他片不僅達到主要療效終點，還可長期維持血紅蛋白（Hb）水平達標，安全性良好，同時顯著降低鐵調素水平，糾正鐵代謝紊亂。德昔度司他片上市後，將與康哲藥業已商業化的CKD高磷血症創新藥維福瑞形成強大協同效應，實現腎病治療多場景覆蓋。百盧妥（磷酸蘆可替尼乳膏）則於2026年1月獲批白癜風適應症，成為中國首款用於該疾病治療的外用JAK抑制劑，填補了國內白癜風靶向治療的市場空白。2026年3月12日，產品在全國30個省級行政區實現白癜風患者首批處方落地，覆蓋千家公私立醫療機構，同步進駐超1,300家線下藥店及京東平台，並已於3月15日上線阿里健康。截至目前，產品在京東健康、阿里健康兩個平台的合計銷量已超8500支。創新管線進入收穫期，多元創新成果密集兌現從早期進口原研藥代理到全鏈條創新藥企，康哲藥業的戰略轉型已初見成效，憑藉持續的研發投入與深厚的商業化能力，構築起難以複製的競爭壁壘。公司現已形成覆蓋心腎代謝、中樞神經、消化、眼科、皮膚健康等高價值專科領域的梯度化管線，7款已上市創新藥合計峰值潛力超百億元，多款產品成為細分領域標杆。在審評中的創新管線產品，同樣具備較高市場潛力。全球首款狂犬病雙特異性抗體斯樂韋米單抗注射液，面向我國每年超4000萬狂犬病毒暴露人群，銷售峰值有望達20億；注射用Y-3作為全球首個基於腦卒中重要靶點PSD95-nNOS和MPO開發的腦細胞保護劑，可實現「卒中治療與卒中後抑鬱焦慮預防」雙重功效，有望重塑急性缺血性卒中治療格局，銷售峰值或將突破30億元；ABP-671為創新型URAT1抑制劑，有望成為可長期服用的、用於優效控制血尿酸水平及優化痛風管理的一線治療首選，銷售峰值亦有望突破30億元。與此同時，康哲藥業正加速完善自主研發體系，研發方向聚焦專科領域的全球前沿靶點，以強化差異化競爭優勢。公司目前包括INHBE小核酸藥物CMS-D008注射液（擬用於超重/肥胖）在內的6款具備全球自主知識產權的創新藥，正在按計劃推進在中國的臨床開發，為其後續增長提供內生動力。創新驅動戰略成效顯著，步入業績兌現與估值修復的良性循環2025年創新藥領域強勢復甦，成為醫藥賽道核心增長引擎。邁入2026，多家機構一致認為創新藥前景依然明朗。隨着技術紅利與國際化能力的雙重疊加，行業正迎來「DeepSeek時刻」，有望湧現出一批十倍股。如何審視其中的中長期機會？又該怎樣捕捉那些具備持續創新力的真正贏家？仔細分析這輪醫藥新股行情，優質創新藥企的價值重估成為核心主線。市場資金正從過去的「泛泛創新」轉向「精選優質」，更加青睞那些擁有核心技術、全鏈路商業化路徑和差異化產品管線的企業，向真創新、實業績、國際化的投資主線聚焦。首先，財務數據是最有力的註腳。康哲藥業2025年銷售收入和正常化利潤重回增長背後，是公司近年來強化產品創新、商業革新、國際拓展三大戰略的轉型成效。通過海外授權、國內合作、自主研發的三位一體研發體系，公司搭建起覆蓋多領域、梯隊完整的創新產品矩陣，護城河日益穩固。其次，公司商業化體系持續革新，院內院外一體、線上線下融合，專業臨床價值與消費醫療需求共振，推動價值釋放步入快車道。作為運營超三十年的平台型企業，商業化能力是康哲藥業的核心競爭力之一。公司目前在售產品超20款，億活、施圖倫、喜遼妥等一批具備市場獨佔性的獨家產品持續穩健增長；另外還有自2023年起推出的創新產品如維福瑞、益路取等正快速放量，構成「獨家品牌驅動、創新引領增長」產品組合。再次，通過聚焦專科，打造細分小領域的大龍頭，獨立運營皮膚健康與眼科業務。2025年4月，康哲藥業啟動皮膚健康業務主體德鎂醫藥的分拆上市計劃。德鎂醫藥構建了覆蓋白癜風、銀屑病、特應性皮炎等疾病的完整產品矩陣，管線合計峰值潛力超120億元。2025年，德鎂醫藥營收10.70億元，同比大增73.20%，分拆後有望獲得更貼合創新藥企的估值溢價。此外，聚焦眼科領域的康哲維盛也已形成鮮明的專科優勢，以眼科領域為核心驅動，打造了包括施圖倫滴眼液（七葉洋地黃雙苷滴眼液）、EyeOP1青光眼治療儀在內的專業眼科藥械產品組合，並引入諾華兩款眼科王牌產品諾適得、倍優適，打造強勢眼科產品矩陣，致力於打造中國眼科醫藥龍頭。最後，康哲藥業積極探索國際拓展，通過東南亞研發+製造+商業化一體化佈局，打造新地域第二增長曲線。2025年7月康哲藥業在新加坡二次上市，不僅優化了國際資本結構，更能藉助當地政策優勢與區位優勢，為產業出海搭建橋樑。東南亞及中東醫藥市場預計2027年規模分別達651億美元和340億美元，年複合增長率均超9%，人口基數大、醫療需求旺盛的藍海市場將為公司帶來廣闊增量空間。康哲藥業以新加坡為樞紐構建起研發、生產、商業化的全鏈條海外運營體系。公司旗下Rxilient平台已在亞太及中東地區提交近20款產品上市申請，新加坡聯營生產基地（PharmaGend）也已通過美國FDA與新加坡HSA雙認證，具備全球合規生產能力。康哲藥業的新地域第二增長曲線逐步成型。寫在最後：估值重構機遇顯現，機構看好長期成長價值在財報發佈後，信達證券、中金證券、海通國際、第一上海等多家券商機構發佈看好康哲藥業的估值預期研報，給予買入或增持評級，IFIND近一個月一致目標價達18.07港元，較截止3月19日收盤價，上漲空間達32%。海通國際在近期一份研報中認為，康哲藥業2025收入端穩健增長，存量集采產品影響已經基本出清。未來兩年創新產品密集上市，獨家及創新產品拉動銷售穩健增長，並看好蘆可替尼市場前景。信達證券在研報中指出，從靶點維度上看，公司的自主創新資產，緊跟全球熱門靶點，TYK2、INHBE等均為全球製藥巨頭重點攻堅的潛力賽道，公司自研創新能力鋒芒初露。站在新起點，康哲藥業手握全鏈條創新能力與成熟商業化體系，正迎來價值重估與業績增長的雙重機遇，長期投資價值值得期待。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-20

TANAKA Announces Executive Appointments

TOKYO, Mar 20, 2026 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL GROUP Co., Ltd. (Head office: Chuo-ku, Tokyo; Group CEO: Koichiro Tanaka) announces that its Board of Directors tentatively decided, at a meeting held on February 16, 2026, the appointment of new Audit & Supervisory Board Members. The Boards of Directors of each group company—TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd., TANAKA PRECIOUS METAL RETAILING Co., Ltd., and TANAKA ELECTRONICS Co., Ltd.—also tentatively decided on the same appointment.Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-for-media/ TANAKA’s Executive Appointments1. TANAKA PRECIOUS METAL GROUP Co., Ltd. (Effective of March 26, 2026)New PositionName Previous PositionAudit & Supervisory Board MemberNobutaka AokiNewly Appointed *The Audit & Supervisory Board Member is scheduled to be appointed at the Annual General Meeting of Shareholders to be held on March 26, 2026.*Satoru Ochiai is scheduled to retire from the position of Audit & Supervisory Board Member effective March 26, 2026.2. TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. (Effective of March 26, 2026)New PositionName Previous PositionAudit & Supervisory Board MemberNobutaka AokiNewly Appointed Audit & Supervisory Board MemberHiroyuki SakamotoNewly Appointed *The Audit & Supervisory Board Member is scheduled to be appointed at the Annual General Meeting of Shareholders to be held on March 26, 2026.*Satoru Ochiai is scheduled to retire from the position of Audit & Supervisory Board Member effective March 26, 2026.3. TANAKA PRECIOUS METAL RETAILING Co., Ltd. (Effective of March 26, 2026)New PositionName Previous PositionAudit & Supervisory Board MemberNobutaka AokiNewly Appointed *The Audit & Supervisory Board Member is scheduled to be appointed at the Annual General Meeting of Shareholders to be held on March 26, 2026.*Satoru Ochiai is scheduled to retire from the position of Audit & Supervisory Board Member effective March 26, 2026.4. TANAKA ELECTRONICS Co., Ltd. (Effective of March 26, 2026)New PositionName Previous PositionAudit & Supervisory Board MemberNobutaka AokiNewly Appointed *The Audit & Supervisory Board Member is scheduled to be appointed at the Annual General Meeting of Shareholders to be held on March 26, 2026.*Satoru Ochiai is scheduled to retire from the position of Audit & Supervisory Board Member effective March 26, 2026.Press Release: https://www.acnnewswire.com/docs/files/20260320.pdf  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-20